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A B S T R A C T
Background
Various hormone therapies (HT) are available to treat menopausal vasomotor symptoms. Bioidentical hormones are chemically identical
to those produced by the human body, and several types are well-tested and available on prescription. Many women have opted for
bioidentical hormone therapy (BHT) on the assumption that it is safer than other forms of HT. We evaluated the evidence.
Objectives
To determine the effectiveness and safety of bioidentical hormones compared to placebo or non-bioidentical hormones for the relief of
vasomotor symptoms.
Search methods
In July 2015 we searched the Cochrane Central Register of Controlled Trials, PubMed, Embase, Literatura Latino-Americana e do
Caribe em Ciências da Saúde (LILACS), registers of ongoing trials and the reference lists of articles retrieved.
Selection criteria
Randomised controlled trials (RCTs) comparing bioidentical hormone therapy (BHT) versus placebo or non-bioidentical hormones.
Data collection and analysis
Weused standardmethodological procedures expected by theCochrane Collaboration. Our primary outcome was vasomotor symptoms
(hot flushes and night sweats). We evaluated the overall quality of the evidence using Grading of Recommendations Assessment,
Development and Evaluation criteria (GRADE).
Main results
We included 23 RCTs (5779 participants). Most studies (20/23) included only women with moderate to severe hot flushes. All studies
compared unopposed 17 beta-estradiol (beta-estradiol) versus placebo or conjugated equine estrogens (CEE). None of the studies
reported night sweats as a separate outcome.
BHT patch versus placebo
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Frequency of hot flushes
Four RCTs reported data suitable for analysis. There were fewer hot flushes in the BHT group, with a moderate to large effect size
(SMD -0.68, 95% CI -0.83 to -0.53, four RCTs, 793 women, I2 = 67%, low quality evidence). There was moderate heterogeneity,
but a consistent direction of effect. Seven RCTs reported data unsuitable for analysis; all reported a benefit in the intervention group.
Symptom intensity
Two RCTs reported analysable data. Measured on a 0-100 visual analogue scale (VAS), hot flush intensity was lower in the BHT
group (MD -19.94 points, 95% CI -24.86 to -15.02, two RCTs, 393 women, I2 = 54%, low quality evidence). There was moderate
heterogeneity, but a consistent direction of effect.
Adverse effects
Adverse events (such as headache, vaginal bleeding, breast tenderness and skin reactions) were more common in the intervention group
(odds ratio (OR) 2.14, 95%CI 1.29 to 3.54, 9 RCTs, 1822 women, I2 = 73%, low quality evidence). There was moderate heterogeneity,
but a consistent direction of effect. In one study, five women in the intervention group developed endometrial hyperplasia.
BHT gel versus placebo
Hot flush frequency
Three RCTs reported this outcome, but the data were unsuitable for analysis. All reported a benefit in the BHT group.
Adverse effects
Adverse events were more common in the BHT group (OR 1.41, 95% CI 1.09 to 1.83, 3 RCTs, 1086 women, I2 = 0%, moderate
quality evidence).
Oral BHT versus placebo
Hot flush frequency
Two studies reported analysable data. There were fewer hot flushes in the BHT group, with a moderate to large effect size (SMD -0.80,
95% CI -1.03 to -0.57, two RCTs, 356 women, I2 = 14%, low quality evidence).
Adverse effects
There was no evidence of a difference between the groups (OR 1.28, 95% CI 0.84 to 1.96, 3 RCTs, 433 women, I2 = 0%, low quality
evidence).
Topical BHT emulsion versus placebo
Hot flush frequency
One study with data unsuitable for analysis reported a benefit in the intervention group.
Adverse effects
There was no evidence of a difference between the groups (OR 1.46, 95%CI 0.80 to 2.66, one RCT, 200 women, low quality evidence).
Intranasal BHT versus placebo
Hot flush frequency
Only one study reported analysable data. There were fewer hot flushes per day in the BHT group (MD -3.04 95% CI -4.05 to -2.03,
one study, 458 women, moderate quality evidence)
Adverse effects
Adverse events (such as headache, breast tenderness, arthralgia and nausea) were more common in the intervention group (OR 1.96,
95% CI 1.26 to 3.03, one RCT, 458 women, moderate quality evidence).
Subgroup analyses
Subgroup analyses by dose of BHT suggested that higher doses of BHT may be associated with more effectiveness but also higher risk
of adverse effects.
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BHT patch versus 0.625 mg CEE
Two RCTs reported this comparison, but the data were unsuitable for analysis.
Hot flush frequency
Both RCTs reported no evidence of a difference between the groups.
Adverse effects
Findings were inconsistent. In one comparison (0.1 mg BHT versus CEE), breast pain and vaginal bleeding were more frequent in the
BHT group.
Oral BHT versus 0.625 mg CEE
Hot flush frequency
One study with data unsuitable for analysis reported no evidence of a difference between the groups.
Adverse effects
There was no evidence of a difference between the groups (OR 1.20, 95% CI 0.50 to 2.87, one RCT, 103 women, very low quality
evidence).
Authors’ conclusions
There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate
to severe menopausal hot flushes. There was low to moderate quality evidence of higher rates of adverse effects such as headache,
vaginal bleeding, breast tenderness and skin reactions in the BHT group. There was some evidence to suggest that higher doses of
BHT are associated with greater effectiveness but also with higher risk of adverse effects. Although all the included studies used
unopposed estrogen, it is recommended best practice to use progestogen therapy in women with a uterus taking estrogen in order to
avoid endometrial hyperplasia, regardless of the source of the estrogen. No data are yet available about the safety of BHT with regard
to long-term outcomes such as heart attack, stroke and breast cancer.
There was no good evidence of a difference in effectiveness between BHT and CEE, and findings with regard to adverse effects were
inconsistent. The quality of the evidence was too low to reach any firm conclusions.
The main limitations in the quality of the evidence were study risk of bias (mainly due to poor reporting of methods), imprecision and
lack of data suitable for analysis.
P L A I N L A N G U A G E S U M M A R Y
Bioidentical hormones for vasomotor menopausal symptoms (hot flushes or night sweats)
Review question
This Cochrane review evaluates the effectiveness and safety of bioidentical hormone treatment (BHT) compared to no treatment or
non-bioidentical hormone treatment (HT) for vasomotor symptoms experienced during the menopausal transition period.
Background
Various hormone therapies (HT) are available to treat menopausal vasomotor symptoms. Bioidentical hormones are chemically identical
to those produced by the human body, and several types are well-tested and available on prescription. Many women have opted for
bioidentical hormone therapy (BHT) on the assumption that it would be safer than other forms of HT. However, as it is unclear
whether BHT is better or safer than other forms of HT, we evaluated the evidence.
Study characteristics
This review includes 23 randomised controlled trials conducted up to July 2015. These studies included a total of 5779 women
who were in the menopausal transition period and suffered from hot flushes. Most of the studies (20/23) included only women with
moderate to severe hot flushes. None of the studies reported night sweats as a separate outcome.
Key results
3Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
There is low to moderate quality evidence that BHT in various forms and doses is more effective than placebo in decreasing the
frequency of moderate to severe hot flushes in women in the menopausal transition period. There was low to moderate quality evidence
of higher rates of adverse effects such as headache, vaginal bleeding, breast tenderness and skin reactions in the BHT group. There is
some evidence to suggest that higher doses of BHT are associated with more effectiveness but also higher risk of adverse effects. No data
are yet available about the safety of BHT with regard to long-term outcomes such as heart attack, stroke and breast cancer. All women
with a uterus who are taking any form of estrogen require co-administration of a progestogen, as unopposed estrogen is associated with
endometrial hyperplasia.
There is no good evidence of a difference in effectiveness between BHT and CEE, and findings with regard to adverse effects are
inconsistent. The quality of the evidence is too low to reach any firm conclusions for this comparison.
Quality of the evidence
The main limitations in the quality of the evidence were study risk of bias (mainly due to poor reporting of methods), imprecision and
lack of data suitable for analysis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Transdermal beta-estradiol patch versus placebo for women with hot f lushes
Population: women with hot f lushes
Setting: community
Intervention: beta-estradiol transdermal patch
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Transdermal beta-estradiol patch versus
placebo for women with hot flushes
Frequency of hot
f lushes
Beta-estradiol patch 0.
0375-0.10 mg/ day
There were fewer hot f lushes in the beta-estradiol group. The ef fect size
was moderate to large (SMD -0.68, 95% CI -0.83 to -0.53)
793
(4 RCTs)
⊕⊕©©
low1,2
Eight studies with data
unsuitable for analy-
sis all f ound a bene-
f it f or the beta-estra-
diol group. They ut ilised
doses ranging f rom 0.
014 mg/ d to 2 mg/ d
Intensity of hot f lushes
Beta-estradiol patch 0.
025-0.05 mg/ day
Measured on a 0-100 VAS, the intensity of hot f lushes was lower in the
beta-estradiol group (MD -19.94 points, 95%CI -24.86 to -15.02)
393
(2 RCTs)
⊕⊕©©
low1,3,4
Adverse ef fects
Beta-estradiol patch
dose 0.10 mg/ day
Rate in placebo group:
144 per 1000
Rate in beta-estradiol
group* : 265 per 1000
(178 to 373)
OR 2.14
(1.29 to 3.54)
1822
(9 RCTs)
⊕⊕©©
low1,5
The rate of adverse ef -
fects was higher in the
beta-estradiol group
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io; MD: mean dif ference; SMD: standardised mean dif ference; mg/ d: m illigrams per day
5
B
io
id
e
n
tic
a
l
h
o
rm
o
n
e
s
fo
r
w
o
m
e
n
w
ith
v
a
so
m
o
to
r
sy
m
p
to
m
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1. Downgraded one level for serious risk of bias: inadequate explanat ion of study methods
2. Downgraded one level for serious inconsistency: I2= 67%. Heterogeneity due to unexplained larger ef fect in the lowest-dose
study. Direct ion of ef fect consistent
3. Downgraded one level for serious inconsistency: I2= 54%. Heterogeneity due to larger ef fect in the highest-dose study.
Direct ion of ef fect consistent
4. Downgraded one level for serious imprecision: small overall sample size
5. Downgraded one level for serious unexplained inconsistency: I2= 73%. Direct ion of ef fect consistent
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B A C K G R O U N D
Description of the condition
According to the criteria proposed by the Stages of Reproductive
Aging Workshop (STRAW), the late menopausal transition (stage
1) is marked by the occurrence of times when menstrual periods
are absent (amenorrhoea) for periods lasting 60 days or more. The
late menopausal transition is characterised by increased variability
in menstrual cycle length, extreme fluctuations in hormonal lev-
els, and increased prevalence of anovulation (failure of a woman’s
ovary to produce eggs). Follicle stimulating hormone (FSH) levels
are sometimes elevated into the menopausal range (over 25 IU/
L) and sometimes they are within the range of the earlier repro-
ductive years, especially in association with high levels of 17 beta-
estradiol (beta-estradiol). This stage is estimated to last an average
of one to three years. Symptoms, most notably vasomotor symp-
toms, are likely to occur during this stage (Harlow 2012) which
usually occurs between 40 to 65 years of age and corresponds to
the period when a woman passes from the reproductive stage of life
through the premenopausal transition andmenopause to the post-
menopausal years (Speroff 2011; Sturdee 2011). The hormone
change associated with the menopausal transition can lead to a
wide variety of symptoms that may negatively affect a woman’s
quality of life. The most common symptoms include hot flushes
(flashes), night sweats, emotional lability, poor concentration and
sleep disturbances. These symptoms can range frommild to severe
(Speroff 2011).
The most common symptoms associated with menopause are hot
flushes, night sweats, sleep disturbance, vaginal atrophy, and dys-
pareunia (NAMS 2012) In most women, these symptoms per-
sist for a year or two after the menopause, but in some they may
continue for 10 or more years. Vasomotor symptoms include hot
flushes and night sweats. The hot flush is described as a sudden
onset of reddening of the skin over the head, neck and chest ac-
companied by a feeling of warmth, often associated with sponta-
neous sweating, palpitations, and anxiety, resulting from a vaso-
motor response caused by decreased beta-estradiol levels (Nelson
2006). This aura is followed by measurable increased heat over the
entire body surface. The duration of these episodes varies from a
few seconds to several minutes and rarely they can last up to one
hour. Flushes are more frequent and severe at night (when they are
called night sweats) or during times of stress (Kronnenberg 1992).
The physiology of vasomotor symptoms is still not yet completely
understood, but they apparently originate in the hypothalamus
and are brought about by a decline in beta-estradiol. However,
not all hot flushes are due to beta-estradiol deficiency. The corre-
lation between the onset of flushes and beta-estradiol reduction is
clinically supported by the effectiveness of beta-estradiol therapy
and absence of flushes in permanent hypo-estradiol states, such
as gonadal dysgenesis (Freedman 2001; Freedman 2006; Wilkin
1981). Among themany theories to explain why hot flushes occur,
one of the most accepted (Tartaryn 1981) hypothesises that hot
flushes are thermoregulatory events that aim to keep the body´ s
temperature within a narrow thermoneutral zone. The brain has
a thermoregulating centre, or thermostat, that constantly checks
the body’s core temperature to ensure that it is within a specific
range. Small increases in body temperature above a certain upper
threshold trigger the brain to induce disseminated peripheral cu-
taneous vasodilation and sweating to dissipate heat and to lower
the body’s temperature again. In many menopausal women, for
reasons related to beta-estradiol fluctuation not yet completely un-
derstood, this upper threshold of the brain’s thermostat is lowered
thus leading the brain to trigger heat dissipating mechanisms sev-
eral times during the day and night, causing the repeated episodes
of hot flushes that are typically reported by women in this period
of their lives. The relationship between the luteinising hormone
(LH) surge and the brain’s lowering of the sweating threshold is
not yet completely clear (Cagnacci 2002).
Description of the intervention
The treatment of choice for moderate to severe vasomotor symp-
toms is estrogen therapy with or without a progestogen (NAMS
2012; Speroff 2011). For healthy women with annoying vasomo-
tor symptoms, especially for those under 60 years of age andwithin
the first 10 years after menopause, hormone therapy (HT) is still a
reasonable choice. Physicians are advised to use the smallest effec-
tive dose for the shortest duration possible (Shifren 2010). Various
preparations of HT can be prescribed for women in menopausal
transition, including bioidentical hormone therapy (BHT). Ac-
cording to the Endocrine Society, a biodentical hormone is a com-
pound that is “identical in structure to that which is produced in
the human body” (ES 2006).
Many well-tested, government-approved, brand-name HT prod-
ucts are bioidentical hormones. Bioidentical beta-estradiol is
aproved by the US Food and Drug Administration (FDA), is
derived from plant sources and is available in the form of pills,
patches, nasal sprays, creams, gels, and vaginal tablets. Bioiden-
tical progesterone is also available in FDA-approved preparations
(such as oralmicronised progesterone in oil or vaginal progesterone
gel) (Shifren 2007; Sturdee 2011). The European Medicines
Agency Pre-authorisationEvaluation ofMedicines forHumanUse
(EMEA 2005) recommends beta-estradiol alone or a combination
of beta-estradiol plus progestogen for the treatment of beta-estra-
diol deficiency symptoms in postmenopausal women.
The findings of the combinedHT arm of theWomen’s Health Ini-
tiative (WHI) trial raised serious concerns about the safety of HT.
Combined HT (conjugated equine estrogen (CEE) 0.625 mg/d
plusmedroxyprogesterone acetate (MPA) 2.5mg/d)was compared
with placebo, and women in the intervention arm had increased
rates of breast cancer, coronary heart disease (CHD), stroke and
pulmonary embolus (Rossouw 2002). TheWHI trial showed that
HT is not suitable for long-term prevention of CHD and that for
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any type of HT therapy the baseline risk profile of the individual
woman must be taken into account (Rossouw 2013). These find-
ings changed attitudes to HT and many women stopped taking it.
Studies have shown that perimenopausal and menopausal women
perceive complementary therapies as being safer and more effec-
tive because they are more ’natural’ (Adams 2001; Kaufert 1998;
Seidl 1998). Some opted for alternative therapies such as foods or
supplements enriched with phytoestrogens (Hersh 2003, Lethaby
2013). Similarly, many women regard BHT as a safer alternative
to other forms of HT (Drisko 2000; NAMS 2012).
How the intervention might work
Vasomotor symptoms associatedwith the onset ofmenopause have
been shown to decline in a linear fashion as estrogen levels are
elevated with replacement therapy (Corson 1993), and in this
respect BHT has the same action as other forms of HT.
Why it is important to do this review
Diminished sleep quality, irritability, difficulty concentrating, and
subsequently reduced quality of life (QOL) are potential conse-
quences of the vasomotor symptoms typical of the menopausal
transition (NAMS 2012). Some common HTs include synthetic
oestrogens alone or combined with progestogens, and these op-
tions have benefits and risks. The use of BHT has escalated in
recent years. It is necessary to look at the best available evidence
on the effectiveness and safety of BHT. This review aims to assess
the effectiveness and safety of the specific subgroup of bioidenti-
cal beta-estradiol and progesterone formulations for the relief of
vasomotor symptoms (NAMS 2012).
O B J E C T I V E S
To determine the effectiveness and safety of bioidentical hormones
compared to placebo or non-bioidentical hormones for the relief
of vasomotor symptoms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing BHT for the re-
lief of vasomotor symptoms with placebo or with non-bioidentical
hormones.
Types of participants
Women in the menopausal transition (spontaneous or surgical
menopause) with vasomotor symptoms.
Types of interventions
Prescription of bioidentical compared with prescription of non-
bioidentical hormones.
Bioidentical hormones are compounds with a molecular and
chemical structure identical to hormones produced by the ovary.
We included in this review bioidentical estrogen (beta-estradiol)
alone or in combination with progesterone, used in any dose or
route of administration in the first group.
In the comparison group we included women receiving non-
bioidentical hormones, such as equine products, estradiol valer-
ate, estropipate (piperazine estrone sulfate) or ethinyl estradiol
alone or in combination with various progestogens (medrox-
yprogesterone acetate, norethindrone, norethindrone acetate,
drospirenone, dienogest) administered in cyclic or continuous reg-
imens. Other drugs used for the relief of vasomotor symptoms
were not included in this review.
Types of outcome measures
Primary outcomes
1. Frequency or intensity of vasomotor menopausal symptoms
(hot flushes or night sweats) measured by any validated scale.
Secondary outcomes
2. Incidence and severity of adverse effects.
3. Quality of life evaluated with any validated instruments used for
quality of life measures, such as the Menopause-Specific Quality
of Life (Hilditch 1996), Women’s Health Questionnaire (Hunter
1992), or other generic measures.
Search methods for identification of studies
Electronic searches
We searched the following sources: Cochrane Central Register
of Controlled Trials (CENTRAL; 2015 Issue 7), PubMed (from
inception to 29th July 2015), Embase (from inception to 29th July
2015), Literatura Latino-Americana e do Caribe em Ciências da
Saúde (LILACS) (from 1982 to 29th July 2015) in consultation
with the Brazilian Cochrane Centre, see Appendix 1, Appendix 2,
Appendix 3, Appendix 4.
We searched for ongoing trials in the following websites:
• metaRegister of Controlled Trials (www.controlled-
trials.com);
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• US National Institutes of Health ongoing trials register
(www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch);
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
There were no language restrictions and we planned to seek trans-
lations if necessary.
Searching other resources
We screened the reference lists of the included studies for addi-
tional potentially relevant studies and contacted specialists in the
field for any possible unpublished data.
Data collection and analysis
Selection of studies
Two review authors (AMISG, SSS) independently screened the
trials identified by the literature search. After merging the search
results and removing duplicate records, the review authors exam-
ined titles and abstracts to select the relevant reports. They then
retrieved and examined the full texts of selected studies for com-
pliance with eligibility criteria and documented the reasons for ex-
clusion of individual trials. They consulted a third author (EMKS
or CRM) if any disagreements arose (at this or at any other stage
as listed below).
Data extraction and management
Two review authors (AMISG, SSS) extracted data independently
using an extraction form designed and pilot-tested by the review
author team. Where studies had multiple publications, we used
the main trial report as the reference and additional details were
supplemented from secondary papers. The review authors resolved
disagreements by consensus or by discussion with a third author.
We contacted the authors from all studies with incomplete infor-
mation on outcomes of interest or additional missing details.
Assessment of risk of bias in included studies
We assessed the included studies for risk of bias using the ’criteria
for judging risk of bias’ outlined in the Cochrane tool for assessing
risk of bias (Higgins 2011a). The analysis included the following:
sequence generation; allocation concealment; blinding of partici-
pants, providers and outcome assessors; incomplete outcome data;
selective outcome reporting; and other potential sources of bias.
Two review authors independently assessed risk of bias. They re-
solved disagreements by consensus or discussion with a third au-
thor. All judgments were fully described and justified.
Measures of treatment effect
We expressed dichotomous data as odds ratios (OR) with 95%
confidence intervals (CIs). For continuous data, we calculated
mean differences (MD) and 95% CIs between treatment groups
if studies reported exactly the same outcomes. If similar outcomes
were reported on different scales, we calculated the standardised
mean difference (SMD) and 95% CI.
Data were collected at three months or at the end of the study, or
both, for the following outcomes:
• hot flush frequency - continuous;
• hot flush severity
◦ continuous,
◦ dichotomous (present versus absent, moderate to
severe versus mild to absent) or
◦ categorical (i.e. the number of women in each severity
category);
• quality of life scores - continuous; and
• adverse events - dichotomous.
Where data to calculate SMDs or ORs were not available, we used
the most detailed numerical data available that might facilitate a
similar analysis of included studies (for example test statistics, P
values).
When studies reported sufficient detail to calculate mean differ-
ence but gave no information on the associated standard devia-
tion (SD), we assumed the outcome to have a SD equal to the
highest SD from other studies using the same assessment scale.
We compared the magnitude and direction of effects reported by
studies with how they were presented in the review, taking into
account legitimate differences. We included both data reported
as final mean scores in each group and mean change scores from
baseline in each group.
Where studies reported both values, we preferentially included
mean change scores from baseline. For the purpose of interpreta-
tion, we considered a SMD between 0.2 and 0.5 as a small effect;
between 0.5 and 0.8 as a moderate effect; and higher than 0.8 as a
large effect. We reported data unsuitable for analysis in additional
tables.
Unit of analysis issues
The unit of analysis was the individual participant (unit to be
randomised for interventions to be compared), that is, the number
of observations in the analysis matched the number of individuals
randomised.
Dealing with missing data
In cases of missing outcomes, or any uncertainty regarding the
data, we contacted the authors asking for the missing data or clari-
fication. In the case of no response, irrespective of the type of data,
we reported dropout rates in the ’Characteristics of included stud-
ies’ table and used intention-to-treat analyses. We imputed only
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the missing data of the primary outcome (vasomotor symptoms)
with replacement values. For dichotomous outcomes we assumed
the missing data to be treatment failures, and for continuous out-
comes we imputed the mean observed. In the absence of standard
deviations, we calculated it when possible from standard errors,
confidence intervals, and P values for differences in means accord-
ing the Cochrane Handbook (Higgins 2011b).
We performed sensitivity analyses by excluding the participants
with missing data to assess the strength of the results.
Assessment of heterogeneity
We quantified inconsistency among the pooled estimates using
the I2 = ((Q - df )/Q) x 100%) statistic, where Q is the Chi2
statistic and df represents the degree of freedom. This illustrates
the percentage of the variability in effect estimates resulting from
heterogeneity rather than sampling error (Deeks 2011).
The thresholds for the interpretation of I2 were as follows:
• 0% to 25%, low heterogeneity;
• 25% to 75%, moderate;
• more than 75%, substantial heterogeneity (Higgins 2003).
Assessment of reporting biases
We planned to minimise the potential impact of publication bias
and other reporting biases by ensuring a comprehensive search for
eligible studies, and by being alert for duplication of data. If 10
or more studies were included in an analysis, we planned to use a
funnel plot to investigate the possibility of small study effects (a
tendency for the intervention to have a bigger impact in smaller
studies).
Data synthesis
If no substantial heterogeneity was identified, we performed
pooled estimates of the treatment effect for each outcome under
a fixed-effect model. If substantial heterogeneity was identified,
we performed a random-effects model analysis. The analyses were
stratified by dose of BHT. When there were several intervention
groups with different doses and a single control group, we divided
the control group data to allow pooling without double-counting
of data, and gave details in a footnote to the analysis. (Analysis
5.1; Analysis 5.2)
We conducted separate comparisons according the route of ad-
ministration of the intervention.
Subgroup analysis and investigation of heterogeneity
If substantial heterogeneity was found, and there were sufficient
data, we planned to explore the possible causes by using subgroup
analyses. If data were available, we intended to conduct the fol-
lowing subgroup analyses.
• Type of menopause: natural; induced; not specified.
• Participants’ baseline status: women with vasomotor
symptoms; women with other associated symptoms.
As noted above, we conducted separate comparisons according the
route of administration of the intervention.
Sensitivity analysis
We planned to conduct sensitivity analyses for the primary out-
comes to determine whether the conclusions were robust to arbi-
trary decisions made during the review process regarding the eli-
gibility for end analysis.
These analyses included consideration of whether the review con-
clusions would have differed if eligibility was restricted to studies
without high risk of bias (studies with high risk of bias for one or
more key domains).
Overall quality of the body of evidence: ’Summary of
findings’ table
We created a ’Summary of findings’ table using GRADEpro
Guideline Development Tool (GRADEpro GDT 2015). This ta-
ble evaluated the overall quality of the body of evidence for the
main review outcomes (vasomotor menopausal symptoms and ad-
verse effects) and the most clinically relevant comparisons, using
GRADE criteria (study limitations (i.e. risk of bias), consistency
of effect, imprecision, indirectness and publication bias). Judge-
ments about evidence quality (high, moderate or low) was justi-
fied, documented, and incorporated into reporting of results for
each outcome.
R E S U L T S
Description of studies
Results of the search
The last search was performed on 29 July 2015 and yielded 2433
records which were reduced to 1923 after the exclusion of dupli-
cates. We excluded a total of 1851 references based on the title
and abstract and selected 72 for full-text reading: we excluded 50
of these because they did not fulfil the selection criteria, and 23
studies were included in the review (Figure 1).
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11Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Trial design
All of the trialswere double-blind, placebo-controlled, randomised
clinical trials. Most of the included studies were multicentre stud-
ies conducted in the USA (Archer 1992; Archer 2003; Archer
2012; Buster 2008; Cohen 1999; Good 1999; Gordon 1995;
Notelovitz 2000a; Notelovitz 2000b; Simon 2006; Speroff 1996a;
Speroff 1996b; Utian 1999) or USA and Canada (Simon 2007).
Three studies were conducted in Italy (Bacchi-Modena 1997; De
Aloysio 2000; Rovati 2000) and the others were conducted in Asia
(Haines 2009), Denmark (Nielsen 2006), Germany (von Holst
2000), Japan (Honjo 2009), Sweden (Wiklund 1993), and The
Netherlands (De Vrijer 2000).
Four studies contained statements declaring that they were sup-
ported by the pharmaceutical industry (Good 1999; Notelovitz
2000a; Speroff 1996a; Speroff 1996b)
Participants
The studies included a total of 5779 women, who were either
naturally or surgically (bilateral oophorectomy)menopausal.Most
of the studies (20/23) included only women with moderate to
severe vasomotor symptoms.
The durationof naturalmenopause ranged fromat least sixmonths
(Archer 2003; Archer 2012;Buster 2008; De Aloysio 2000; Good
1999; Notelovitz 2000a; Rovati 2000; Wiklund 1993 ) to eight to
12 months (Bacchi-Modena 1997; Cohen 1999; De Vrijer 2000;
Gordon 1995; Honjo 2009; Haines 2009; Notelovitz 2000b;
Simon 2006; Simon 2007; Utian 1999) and up to five years
(Nielsen 2006). Three studies (Speroff 1996a; Speroff 1996b;
Archer 1992) did not report the time undergone since natural
menopause of their participants. For the surgically menopausal
participants, the time since bilateral oophorectomy ranged from
two to four weeks (De Aloysio 2000; Gordon 1995; Honjo
2009; Notelovitz 2000b; Speroff 1996a) to at least six weeks
(Bacchi-Modena 1997; Cohen 1999; De Vrijer 2000; Nielsen
2006; Haines 2009; Rovati 2000; Simon 2007; Utian 1999 ;
von Holst 2000; Wiklund 1993) up to one year or more before
study entry (Simon 2006). Six studies, (Archer 1992; Archer 2003;
Archer 2012; Buster 2008; Good 1999; Notelovitz 2000a) did not
report the time between surgical menopause up to study entry.
Archer 2003, Good 1999, De Vrijer 2000, De Aloysio 2000,
Notelovitz 2000b and Utian 1999 excluded women who had re-
ceived oral, transdermal, or vaginal steroid hormones (beta-estra-
diols, progestogens or corticosteroids) in the last six to eight weeks
prior to enrolment. De Vrijer 2000, De Aloysio 2000, Gordon
1995 and Rovati 2000 stated that they excluded women who had
received implants in the 12 preceding months, or with any pre-
vious unopposed beta-estradiol use for more than three months.
Bacchi-Modena 1997, Cohen 1999, Simon 2006 and von Holst
2000 excluded women who had used transdermal HT in the last
21 days to two months or oral hormones in the last 28 days to
eight weeks, or six weeks vaginal beta-estradiol, or injection or
implants in the three to six months preceding trial entry. The
other studies (Archer 1992; Archer 2012; Buster 2008; Honjo
2009;Haines 2009;Nielsen2006;Notelovitz 2000a; Simon2007;
Speroff 1996a; Speroff 1996b; Utian 1999; Wiklund 1993) did
not specify washout periods for the participants before entry in
the trials.
All the trials reported confirmation of ovarian failure by measure-
ment of FSH levels. Postmenopausal status was confirmed through
serum estradiol concentration < 20 pg/mL, serum FSH level at
least 40-50 mIU/mL and a minimum of 3-7 hot flushes per day
or 56-60 hot flushes per week of moderate to severe intensity.
Nielsen 2006 included women who were fewer than five years past
menopause at study entry and had serum estradiol levels below
0.16 nmol/L and FSH levels above 42 IU/L.
We have presented full details of the inclusion and exclusion cri-
teria in the ’Characteristics of included studies’ table.
Interventions
Eleven studies compared the effects of transdermal beta-estradiol
patches (0.014, 0.02, 0.025, 0.0375, 0.04, 0.05, 0.1 and 0.2 mg/
d) versus placebo on hot flush frequency, severity, or both (Bacchi-
Modena 1997; Cohen 1999; De Aloysio 2000, De Vrijer 2000;
Haines 2009; Rovati 2000; Speroff 1996a; Speroff 1996b; Utian
1999; von Holst 2000; Wiklund 1993).
Three studies (Archer 2003; Archer 2012; Simon 2007) used beta-
estradiol gel (0.27 mg/d; 0.37 mg/d; 0.5 mg/d; 0.75 mg/d; 1.0
mg/d and 1.5 mg/d).“
Four studies compared oral beta-estradiol (0.1 mg/d; 0.25 mg/d;
0.5 mg/d; 1.0 mg/d; 1.2 mg/d and 2 mg/d) with placebo (Archer
1992; Honjo 2009; Notelovitz 2000a; Notelovitz 2000b).
One study compared micellar nanoparticle beta-estradiol emul-
sion versus placebo (Simon 2006).
Two studies (Buster 2008; Nielsen 2006) used intranasal spray
(0.021 mg/d; 0.029 mg/d; 0.040 mg/d; 150 µg/d; and 300 µg/d)
as the mode of beta-estradiol delivery.
Three studies compared transdermal beta-estradiol (0.05 or 0.1
mg/d) or oral beta-estradiol (1 or 2 mg/d) versus 0.625 or 1.25
mg/d oral conjugated equine estradiol (CEE) (Archer 1992; Good
1999; Gordon 1995).
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Outcomes
The trials measured the primary outcome (vasomotor symptoms)
in many different ways. None of the included studies reported
night sweats as a separate outcome. Most commonly, study partic-
ipants recorded the number of episodes over a period of a day or
week, and changes from the baseline indicated treatment response.
Seventeen studies assessed vasomotor symptoms such as hot flush
frequency and severity (Archer 2003; Archer 2012; Buster 2008;
Bacchi-Modena 1997; Cohen 1999; De Aloysio 2000; De Vrijer
2000; Good 1999; Gordon 1995; Honjo 2009; Notelovitz 2000a;
Notelovitz 2000b; Rovati 2000; Simon 2006; Simon 2007; Utian
1999; von Holst 2000).
Four studies assessed only hot flush frequency (Archer 1992;
Haines 2009; Speroff 1996a; Speroff 1996b).
Climacteric symptoms were assessed by the Greene Climacteric
Scale (Buster 2008); Kupperman’s Index (Bacchi-Modena 1997;
De Aloysio 2000; Rovati 2000; von Holst 2000; Wiklund 1993);
and visual analogue scale (VAS). One study did not report data
using a specific vasomotor symptom subscale (Honjo 2009).
Severity was evaluated according to different rating scales ranging
from1 to 3 (mild to severe symptoms) (Archer 2003; Archer 2012;
Buster 2008; Cohen 1999; De Vrijer 2000; Good 1999; Gordon
1995; Honjo 2009; Simon 2006; Simon 2007; Speroff 1996a;
Speroff 1996b; Notelovitz 2000a; Notelovitz 2000b; Utian 1999;
vonHolst 2000) by a VAS scale of 0 to 100 (Bacchi-Modena 1997;
De Aloysio 2000; Rovati 2000) and according to log transforma-
tion of the severity scores obtained.
Most studies reported the mean reduction in average 24-hour
hot flush frequency and severity from baseline to the end or
any time of the study (Archer 1992; Archer 2003; Archer 2012;
Bacchi-Modena 1997; Buster 2008; Cohen 1999; De Aloysio
2000; De Vrijer 2000; Honjo 2009; Notelovitz 2000b; Rovati
2000; Simon 2006; Simon 2007; Utian 1999). Several studies
assessed the mean weekly reduction in frequency and severity of
moderate to severe hot flushes from baseline (Good 1999; Gordon
1995; Haines 2009; Notelovitz 2000a; von Holst 2000). Two
studies used analysis of covariance to compare the frequency of
hot flushes per week (Speroff 1996a; Speroff 1996b). The vaso-
motor symptoms diary was the tool that the included studies used
most frequently to quantify hot flush frequency and severity. For
all RCTs, the frequency of hot flushes was based on the number
of hot flushes recorded per day.
Only three studies reported quality of life as one of their outcomes
(Haines 2009; Nielsen 2006; Wiklund 1993).
All studies reported adverse events.
We imputed SDs for two studies that failed to report them (Bacchi-
Modena 1997; von Holst 2000).
Fourteen of the 23 studies reported data that were unsuitable for
analysis for our primary outcome because data were skewed or
were presented only in graphical form (Archer 1992; Archer 2003;
Archer 2012;DeAloysio 2000;Good 1999;Gordon 1995;Haines
2009; Nielsen 2006; Notelovitz 2000a; Rovati 2000; Speroff
1996a; Speroff 1996b; Simon 2007; Simon 2006). We have re-
ported their findings in additional tables.
Excluded studies
Fifty studies were excluded mainly because they did not include
the intervention or any of the outcomes of interest, or because
of their design. See Characteristics of excluded studies for more
details.
Risk of bias in included studies
See Figure 2 and Figure 3 for the graph and summary of review
authors’ judgements about the risk of bias for included studies.
Figure 2.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Eleven studies (Archer 1992; Archer 2003; Archer 2012;
Bacchi-Modena 1997; Cohen 1999; Good 1999; Gordon 1995;
Notelovitz 2000b Simon 2006; von Holst 2000; ; Wiklund 1993)
were at unclear risk of selection bias because they did not describe
the method of sequence generation. The other studies (Buster
2008; De Aloysio 2000; De Vrijer 2000; Haines 2009; Honjo
2009; Nielsen 2006; Notelovitz 2000a; Rovati 2000; Simon 2007;
Speroff 1996a; Speroff 1996b, Utian 1999) reported adequate
methods of sequence generation and we deemed them to be at low
risk of bias.
Allocation concealment
Eighteen studies (Archer 1992; Archer 2003; Archer 2012; Bacchi-
Modena 1997; Cohen 1999; De Vrijer 2000; Good 1999; Honjo
2009; Haines 2009; Notelovitz 2000a; Notelovitz 2000b; Rovati
2000; Simon 2006; Speroff 1996a; Speroff 1996b; Utian 1999;
von Holst 2000; Wiklund 1993) did not report the method used
for allocation concealment and thuswe considered them at unclear
risk of selection bias. Buster 2008; De Aloysio 2000; Gordon
1995; Nielsen 2006; Simon 2007 reported adequate allocation
concealment methods and we therefore classified them as being at
low risk of bias for this domain.
Blinding
Performance bias
All 23 studies reported that the participants were blinded but only
13 studies provided sufficient details about the blinding (Archer
2003; Buster 2008; De Aloysio 2000; De Vrijer 2000; Good
1999;Gordon 1995;Notelovitz 2000a; Simon 2006; Simon 2007;
Speroff 1996a; Speroff 1996b; Utian 1999; Wiklund 1993) and
we rated them at low risk of performance bias. The other studies
we rated at unclear risk of bias in this domain.
Detection bias
Five studies provided adequate detail about blinding of out-
come assessment and we rated them at low risk of detection bias
(Notelovitz 2000a; Simon 2007; Speroff 1996a; Speroff 1996b;
Wiklund 1993). The other studies described themselves as dou-
ble-blinded but reported inadequate information about blinding
of outcome assessment, and we rated them at unclear risk of de-
tection bias.
Incomplete outcome data
We rated studies at high risk of attrition bias if 20% or more
participants were lost to follow-up, or if losses were over 10% and
unbalanced between the groups. We rated studies at unclear risk
of attrition bias if 10% to 20% of participants were not included
in analysis, and at low risk if fewer than 10% were not included
in analysis.
All studies had loss of participants at follow-up except for one
study which did not provide information on this (De Vrijer 2000).
We deemed eight studies at low risk of bias for this domain
(Bacchi-Modena 1997; Cohen 1999; Haines 2009; Honjo 2009;
Simon 2006; Simon 2007; von Holst 2000; Wiklund 1993).
Three studies reported that losses to follow-up were low and bal-
anced in all groups (Bacchi-Modena 1997; Cohen 1999; Utian
1999). We considered nine studies to be at high risk of attrition
bias because the dropout rates were high or not balanced between
the groups, or both (Archer 1992; Archer 2012; Buster 2008; De
Aloysio 2000; Gordon 1995; Nielsen 2006; Rovati 2000; Speroff
1996a; Speroff 1996b). The other studies were deemed at unclear
risk.
Selective reporting
We rated studies at low risk of selective reporting if they re-
ported all expected outcomes (vasomotor symptoms and adverse
events), including those prespecified in the protocol or methods
sections. Twenty-two studies included all expected outcomes and
we deemed them to be at low risk of reporting bias. We rated risk
of bias for Gordon 1995 as unclear because reporting of adverse
events was limited.
Other potential sources of bias
We rated eight studies at unclear risk of bias due to failure to report
full statistical data, either because data were only presented as a
graph or because no standard deviations were reported. All other
studies were rated at low risk of bias in this domain, as we did not
identify any other source of potential bias.
Effects of interventions
See:Summary offindings for themain comparisonTransdermal
beta-estradiol patch versus placebo for women with hot flushes;
Summary of findings 2 Transdermal beta-estradiol gel versus
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placebo for women with hot flushes; Summary of findings 3
Oral beta-estradiol versus placebo for women with hot flushes;
Summary of findings 4 Topical beta-estradiol emulsion versus
placebo for women with hot flushes; Summary of findings
5 Intranasal beta-estradiol versus placebo for women with hot
flushes; Summary of findings 6 Transdermal beta-estradiol patch
versus conjugated equine estrogens for women with hot flushes;
Summary of findings 7 Oral beta-estradiol versus conjugated
equine estrogens for women with hot flushes
The included studies evaluated the effects of BHT given through
different routes of administration and in different dosages, making
it difficult to conduct meta-analyses. When it was not possible to
performmeta-analyses, we presented a narrative description of the
results.
We present the comparisons as follows:
• Beta-estradiol versus placebo
◦ Transdermal beta-estradiol patch versus placebo (11
RCTs)
◦ Transdermal beta-estradiol gel versus placebo (three
RCTs)
◦ Oral beta-estradiol versus placebo (four RCTs)
◦ Topical beta-estradiol emulsion versus placebo (one
RCT)
◦ Intranasal beta-estradiol versus placebo (two RCTs)
• Beta-estradiol versus conjugated equine estrogens (CEE)
◦ Transdermal beta-estradiol patch versus CEE (two
RCTs)
◦ Oral beta-estradiol versus CEE (one RCT)
1. Beta-estradiol versus placebo
1.1 Transdermal beta-estradiol patch versus placebo (11
RCTs)
1.1.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms measured by any validated scale
Frequency of hot flushes
Four RCTs reported data suitable for pooling. The daily dose
of beta-estradiol was 0.0375 mg/d (Cohen 1999), 0.05 mg/d
(Bacchi-Modena 1997; De Vrijer 2000; von Holst 2000) or 0.10
mg/d (De Vrijer 2000). The SMD analysis was applied due to
differences in the measurement of hot flush frequency (reduction
in the number of hot flushes per week, per day). Our findings
were compatible with a moderate to large benefit in the inter-
vention group (SMD -0.68, 95% CI -0.83 to -0.53, four RCTs,
793 women, I2 = 67%, low quality evidence). There was mod-
erate statistical heterogeneity which was attributable to one study
(Cohen 1999), in which the benefit in the intervention group was
more pronounced; though there was no obvious difference be-
tween Cohen 1999 and the other studies that might account for
this. However, the direction of effect was consistent (Analysis 1.1,
Figure 4).
Figure 4. Forest plot of comparison: 1 Transdermal beta estradiol patch vs placebo, outcome: 1.1
Frequency of hot flushes
Subgroup analysis by dose
All doses of beta-estradiol were associated with a benefit for the
intervention group. There was evidence of a significant differ-
ence between the subgroups (test for subgroup differences: Chi²
= 10.33, df = 2 (P value = 0.006), I² = 80.6%). The difference
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was attributable to Cohen 1999. It was unclear why the effect was
more pronounced in this study, as it utilised the lowest dose of
beta-estradiol.
Findings in studies with data unsuitable for analysis
Wewere unable to extract data suitable for analysis in seven studies.
They utilised a daily dose of beta-estradiol of 0.014 mg (Haines
2009), 0.02 mg (Speroff 1996a; Speroff 1996b) 0.025 mg (De
Aloysio 2000; Rovati 2000; Utian 1999), 0.375 mg (De Aloysio
2000), 0.04mg (Speroff 1996a, Speroff 1996b,) 0.05mg (Gordon
1995; Rovati 2000; Utian 1999) or 0.1 mg (Gordon 1995; Utian
1999). In all comparisons there was a benefit in the intervention
group (see Table 1 for details).
Intensity of hot flushes
Two RCTs reported data suitable for pooling. The daily dose of
beta-estradiol was 0.025 mg (De Aloysio 2000; Rovati 2000),
0.0375 mg (De Aloysio 2000) or 0.05 mg (Rovati 2000). Mea-
sured on a 0 to 100 visual analogue scale (VAS), the intensity of hot
flushes was lower in the intervention group (MD -19.94 points,
95% CI -24.86 to -15.02, two RCTs, 393 women, I2 = 54%, low
quality evidence). There was moderate statistical heterogeneity,
but the direction of effect was consistent (Analysis 1.2).
Subgroup analysis by dose
All doses of beta-estradiol were associated with a benefit for the
intervention group. There was evidence of a significant difference
between the subgroups (test for subgroup differences: Chi² = 6.29,
df = 2, P value = 0.04, I² = 68.2%), which was attributable to the
subgroup which received the highest dose (0.05 mg/d), among
whom the benefit in the intervention groupwasmore pronounced.
Findings in studies with data unsuitable for analysis
We were unable to extract data suitable for analysis in one study,
which compared a weekly 0.014 mg/d transdermal 17 beta-estra-
diol patch versus placebo (Haines 2009). The relative reduction
was larger in the intervention than in the placebo group: -5.8 ver-
sus -8.4, P value < 0.05 (see Table 2 for details).
Secondary outcomes
1.1.2 Incidence and severity of adverse effects
Nine RCTs reported data suitable for pooling. The daily dose of
beta-estradiol was 0.014mg (Haines 2009), 0.025 mg (DeAloysio
2000; Rovati 2000; Utian 1999), 0.0375 mg (Cohen 1999; De
Aloysio 2000), 0.05 mg (Bacchi-Modena 1997; De Vrijer 2000;
Rovati 2000; Utian 1999; von Holst 2000; Wiklund 1993) or
0.10 mg (De Vrijer 2000; Utian 1999).
Adverse events (such as skin irritation, vaginal bleeding and breast
tenderness)weremore common in the intervention arm (OR2.14,
95%CI 1.29 to 3.54, 9 RCTs, 1822women, I2 = 73%, lowquality
evidence). There was moderate statistical heterogeneity, but the
direction of effect was consistent (Analysis 1.3). In one study (De
Vrijer 2000), five women in the intervention group developed en-
dometrial hyperplasia. The heterogeneity was mainly attributable
to the subgroup that had the 0.10 dose of beta-estradiol.
Subgroup analysis by dose
When subgrouped by dose, findings were no longer statistically
significant except for the subgroup of women who had the highest
dose of beta-estradiol (0.10 mg). There was evidence of a signif-
icant difference between the subgroups (test for subgroup differ-
ences: Chi² = 27.48, df = 4, P value < 0.00001, I2 = 85.4%), at-
tributable to amore pronounced effect in this high-dose subgroup.
1.1.3 Quality of life evaluated with any validated instrument
Two studies reported quality of life as an outcome, using a variety
of scales. The daily dose of beta-estradiol was 0.014 mg (Haines
2009) and 0.05 mg (Wiklund 1993).
Haines 2009 reported no evidence of a difference between the
groups, measured on the Menopause Quality of Life (MENQol)
scale (MD 0.00 points, 95% CI -0.35 to 0.35, one RCT, 165
women) (Analysis 1.4).
Wiklund 1993 observed greater improvement in the intervention
group, measured using five different scales (see Analysis 1.5).
1.2 Transdermal beta-estradiol gel versus placebo (three
RCTs)
1.2.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms
There were no data suitable for analysis.
Findings in studies with data unsuitable for analysis (Table 1)
Three studies reported data unsuitable for analysis (Archer 2003;
Archer 2012; Simon 2007). The daily dose of beta-estradiol was
0.27 mg (Archer 2012), 0.37 mg (Archer 2012), 0.5 mg (Simon
2007), 0.75 (Archer 2003), 1.0 (Simon 2007), or 1.5 mg (Archer
2003; Simon 2007). See Table 3 for details.
Archer 2003 and Archer 2012 reported a benefit in the all the
intervention groups compared with the placebo groups (P value <
0.05 and P value < 0.001 respectively).
Simon 2007 also reported that the proportion of women with ad-
equate relief of hot flushes was significantly higher in the inter-
vention groups (P value < 0.001)
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Secondary outcomes
1.2.2 Incidence and severity of adverse effects
Three RCTs reported data suitable for pooling. The daily dose of
beta-estradiol was 0.27mg (Archer 2012), 0.37mg (Archer 2012),
0.5 mg (Simon 2007), 1.0 mg (Simon 2007), or 1.5 mg (Simon
2007).
Adverse events such as headache and breast pain were more com-
mon in the intervention arm (OR 1.41, 95% CI 1.09 to 1.83, 3
RCTs, 1086 women, I2 = 0%,moderate quality evidence) Analysis
2.1.
Subgroup analysis by dose
When subgrouped by dose, findings were no longer statistically
significant except for the subgroup of women who had the highest
dose of beta-estradiol (1.5 mg). however, there was no evidence of
a significant difference between the subgroups (test for subgroup
differences: Chi² = 3.75, df = 5, P value = 0.59, I² = 0%).
1.2.3 Quality of life
This outcome was not reported in the included studies.
1.3 Oral beta-estradiol versus placebo (four RCTs)
1.3.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms
Hot flush frequency
Two studies reported data suitable for pooling. The daily dose
of beta-estradiol was 0.5 mg (Honjo 2009; Notelovitz 2000b)
or 1.0 mg (Honjo 2009; Notelovitz 2000b). The SMD analysis
was applied due to differences in the scale of measures used. Our
findings were compatible with a moderate to large benefit in the
intervention group (SMD -0.80, 95% CI -1.03 to -0.57, 2 RCTs,
356 women, I2 = 14%, low quality evidence) (Figure 5).
Figure 5. Forest plot of comparison: 3 Oral beta estradiol vs placebo, outcome: 3.1 Frequency of hot flushes
Subgroup analysis by dose
When data were subgrouped by dose, a benefit was seen in the
intervention group at both dose levels. There was no evidence of
a significant difference between the subgroups (test for subgroup
differences: Chi² = 2.31, df = 1, P value = 0.13, I² = 56.6%).
Findings in studies with data unsuitable for analysis
Two studies reported data unsuitable for analysis (Archer 1992;
Notelovitz 2000a).
Notelovitz 2000a compared oral micronised beta-estradiol 0.25
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mg, 0.5 mg, 1 mg, or 2 mg versus placebo. Results were reported
only in graphics. The authors reported a significant linear correla-
tion between increased dosage of oral beta-estradiol and decreased
moderate to severe hot flushes at week 12.
Archer 1992 compared 1.0 and 2.0 mg/d of beta-estradiol versus
placebo and reported that hot flush frequency at 12 weeks was
significantly lower in both intervention groups (see Table 4 for
details).
Secondary outcomes
1.3.2 Incidence and severity of adverse effects
Three RCTs reported data suitable for pooling. The daily dose
of beta-estradiol was 0.5 mg (Honjo 2009; Notelovitz 2000b),
1.0 mg (Archer 1992; Honjo 2009; Notelovitz 2000b) or 2 mg/d
(Archer 1992).
There was no evidence of a difference between the groups (OR
1.28, 95% CI 0.84 to 1.96, 3 RCTs, 433 women, I2 = 0%, low
quality evidence) Analysis 3.2.
Subgroup analysis by dose
Subgrouping by dose did not change the statistical significance of
the findings and the test for subgroup differences was not signifi-
cant (test for subgroup differences: Chi² = 1.00, df = 2, P value =
0.61, I² = 0%).
1.2.3 Quality of life
This outcome was not reported in the included studies.
1.4 Topical beta-estradiol emulsion versus placebo (one
RCT)
1.4.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms
One study reported this comparison (Simon 2006). The daily dose
of beta-estradiol was 8.6 mg. Data were unsuitable for analysis. At
the end of week 12, the intervention group had a greater reduction
in the mean number of moderate to severe hot flushes per day (see
Table 5 for details).
Secondary outcomes
1.4.2 Incidence and severity of adverse effects
There was no evidence of a difference between the groups (OR
1.46, 95% CI 0.80 to 2.66, 1 RCT, 200 women, low quality
evidence)
1.4.3 Quality of life evaluated
This outcome was not reported
1.5 Intranasal beta-estradiol versus placebo (two RCTs)
1.5.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms
Only one study reported data suitable for analysis (Buster 2008).
The daily dose of beta-estradiol was one, two or three spray doses,
corresponding to 0.021 mg/d, 0.029 mg/d, and 0.040 mg/d in
Buster 2008. A second study reported data unsuitable for analysis
(Nielsen 2006).
Hot flush frequency
There were fewer hot flushes per day in the intervention group
(MD -3.04 95%CI -4.05 to -2.03, 1 RCT, 458 women, moderate
quality evidence) (Analysis 5.1, Figure 6).
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Figure 6. Forest plot of comparison: 5 Intranasal beta estradiol vs placebo, outcome: 5.1 Frequency of hot
flushes
Subgroup analysis by dose
When data were subgrouped by dose, a benefit was seen in the
intervention group at all dose levels. There was no evidence of
a significant difference between the subgroups (test for subgroup
differences: Chi² = 0.46, df = 2, P value = 0.79, I² = 0%).
Secondary outcomes
1.5.2 Incidence and severity of adverse effects
There was a higher rate of adverse effects (such as headache, breast
tenderness, arthralgia and nausea) in the intervention group (OR
1.96, 95% CI 1.26 to 3.03, 1 RCT, 458 women).
Subgroup analysis by dose
When data were subgrouped by dose, there was no significant
difference between the groups at any dose level. There was no
evidence of a significant difference between the subgroups (test
for subgroup differences: Chi² = 0.03, df = 2, P value = 0.99, I² =
0%).
1.5.3 Quality of life
No studies reported data suitable for analysis for this outcome
Findings in study with data unsuitable for analysis
The Nielsen 2006 study used the Women’s Health Questionnaire
to compare the quality of life of women using intranasal beta-
estradiol 0.15 mg/d or 0.30 mg/d versus placebo.There was an
improvement in both beta-estradiol groups compared to placebo
in the memory and concentration, vasomotor symptoms, sleep
problems and sexual behaviour dimensions (P value < 0.001).
There was no evidence of a difference between the intervention
and placebo groups in the anxiety, depressed mood or well-being
dimensions (see Table 6 for details).
2 Beta-estradiol versus conjugated equine estrogens
2.1 Transdermal beta-estradiol patch versus CEE (two
RCTs)
2.1.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms
No studies reported data suitable for analysis.
Findings in studies with data unsuitable for analysis (see Table 7 for
details).
Two RCTs reported this outcome. They compared beta-estradiol
patches with daily doses of 0.05 mg or 0.1 mg versus CEE 0.0625
mg/d (Good 1999; Gordon 1995) or 1.25 mg/d (Good 1999).
Good 1999 reported that at 12 weeks there was no evidence of a
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difference between any of the groups in the mean number of hot
flushes per week compared with baseline (P value > 0.05).
Gordon 1995 reported that at 11 weeks there was a significant
reduction in the mean number of weekly hot flushes in all three
treatment groups compared with baseline: with no evidence of a
difference between the groups.
Secondary outcomes
2.1.2 Incidence and severity of adverse effects
Good 1999 reported no evidence of a difference between groups in
adverse events. Gordon 1995 reported that breast pain and vaginal
bleeding were more frequent in the 0.1 mg/d beta-estradiol group
than in other groups (P value < 0.05).
2.1.3 Quality of life evaluated with any validated instrument
This outcome was not reported.
2.2 Oral beta-estradiol versus CEE (one RCT)
2.2.1 Primary outcome: frequency or intensity of vasomotor
menopausal symptoms
No studies reported data suitable for analysis
Findings in study with data unsuitable for analysis
Archer 1992 compared oral beta-estradiol 1.0 mg/d or 2.0 mg/
d versus CEE 0.625 mg/d or 1.25 mg/d. After 12 weeks of use,
there was no evidence of a difference between any of the groups
(see Table 8 for details).
Secondary outcomes
2.2.2 Incidence and severity of adverse effects
Archer 1992 reported that there was no evidence of a difference
between the groups in the incidence of possible drug-related ad-
verse effects between the beta-estradiol 1.0 mg/d or 2 mg/d and
CEE 0.625 mg/d or 1.25 mg/d (OR 1.20, 95% CI 0.50 to 2.87,
1 RCT, 103 women, I2 = 0%). See Analysis 6.1.
2.2.3 Quality of life evaluated with any validated instrument
This outcome was not reported.
Other analyses
Sensitivity and subgroup analyses and assessment for
publication bias
As there were too few studies included in any one analysis, we did
not perform a sensitivity analysis to explore the robustness of the
results andwe did not use a funnel plot to investigate the possibility
of small study effects (a tendency for the intervention to have a
bigger impact in smaller studies). Nor were there sufficient data to
perform subgroup analyses by type of menopause or participants’
baseline status.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Transdermal beta-estradiol gel versus placebo
Population: women with hot f lushes
Setting: community
Intervention: beta-estradiol transdermal gel
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Transdermal beta-estradiol gel versus placebo
Frequency of hot
f lushes
Beta-estradiol gel 0.27-
1.5 mg/ day
There were no data suitable for analysis. 3 stud-
ies with data unsuitable for analysis reported a
benef it in the beta-estradiol gel group (P value <
0.05)
930
3 RCTs
⊕©©©
low1
Adverse ef fects
Beta-estradiol gel dose
1.5 mg/ day
Rate in placebo group:
431 per 1000
Rate in beta-estradiol
group* : 516 per 1000
(452 to 581)
0R 1.41
(1.09 to 1.83)
1086
(3 RCTs)
⊕⊕⊕©
moderate2
The rate of adverse ef -
fects was higher in the
beta-estradiol group
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io; mg/ d: m illigrams per day
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1. Downgraded two levels for very serious risk of bias: studies at high or unclear risk of bias in most domains, data unsuitable
for analysis
2. Downgraded one level for serious risk of bias: studies at high or unclear risk of bias in most domains22
B
io
id
e
n
tic
a
l
h
o
rm
o
n
e
s
fo
r
w
o
m
e
n
w
ith
v
a
so
m
o
to
r
sy
m
p
to
m
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Oral beta-estradiol versus placebo
Population: women with hot f lushes
Setting: community
Intervention: oral beta-estradiol
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Oral beta-estradiol versus placebo for women
with hot flushes
Frequency of hot
f lushes
Oral beta-estradiol 0.5-
1.0 mg/ day
There were fewer hot f lushes in the beta-estradiol group. The ef fect size
was moderate to large (SMD -0.80, 95% CI -1.03 to -0.57)
356
(2 studies)
⊕⊕©©
low1,2
Two studies with data
unsuitable for analysis
also reported a bene-
f it in the intervent ion
groups
Adverse ef fects
Oral beta-estradiol 0.5-
2.0 mg/ day
Rate in placebo group:
245 per 1000
Rate in beta-estradiol
group* : 293 per 1000
(214 to 389)
0R 1.28
(0.84 to 1.96)
433
(3 RCTs)
⊕⊕©©
low1,2
There was no evidence
of a dif ference between
the groups
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; SMD: Standardised mean dif ference OR: Odds rat io; mg/ d: m illigrams per day
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1. Downgraded one level for serious risk of bias: studies at high or unclear risk of bias in most domains
2. Downgraded one level for serious imprecision: small overall sample size and/ or wide conf idence interval2
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Topical m icellar nanopart icle beta-estradiol emulsion versus placebo
Population: women with vasomotor symptoms
Setting: community
Intervention: topical m icellar nanopart icle beta-estradiol emulsion
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with Placebo Risk with Topical
micellar nanoparticle
beta-estradiol
Frequency of vasomo-
tor menopausal symp-
toms
Micellar nanopart icle
beta-estradiol 8.6 mg/
day
One study with data unsuitable for analysis reported a benef it in the beta-
estradiol group (P value < 0.001)
200
(1 study)
⊕⊕©©
low1,2
Adverse ef fects
Micellar nanopart icle
beta-estradiol 8.6 mg/
day
650 per 1000 731 per 1000
(598 to 832)
OR 1.46
(0.80 to 2.66)
200
(1 study)
⊕⊕©©
low1,3
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect24
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1Downgraded two levels for very serious risk of bias: methods of randomisat ion not clearly reported, data skewed and
unsuitable for analysis
2Downgraded one level for serious risk of bias: methods of randomisat ion not clearly reported
3Downgraded one level for serious imprecision: f indings compatible with benef it in either group or with no dif ference between
the groups
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Intranasal beta-estradiol versus placebo
Patient or population: women with hot f lushes
Setting: community
Intervention: intranasal beta-estradiol
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Beta-estra-
diol intranasal
Frequency of hot
f lushes
Change f rom baseline
Intranasal beta-estra-
diol 0.021 mg/ day, 0.
029 mg/ day or 0.040
mg/ day
The mean rate of hot f lushes per day was lower in the beta-estradiol group
(MD - 3.04, 95% CI -4.05 to -2.03)
458
(1 RCT)
⊕⊕⊕©
moderate1
Adverse ef fects
Intranasal beta-estra-
diol 0.021 mg/ day, 0.
029 mg/ day or 0.040
mg/ day
171 per 1000 288 per 1000
(206 to 385)
OR 1.96
(1.26 to 3.03)
458
(1 RCT)
⊕⊕⊕©
moderate1
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; MD: mean dif ference; OR: Odds rat io; mg/ d: m illigrams per day
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect26
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Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1. Downgraded one level due to serious risk of attrit ion bias
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Beta-estradiol versus conjugated equine estrogen for hot f lushes
Population: women with hot f lushes
Setting: community
Intervention: beta-estradiol patch
Comparison: conjugated equine estrogen (CEE)
Outcomes Beta-estradiol versus CEE No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Frequency of hot f lushes
Beta-estradiol patch 0.05 or 0.1
mg per day
vs CEE 0.625 or 1.25 mg per day
Two studies with data unsuit-
able for analysis reported no evi-
dence of a dif ference between the
groups
711
(2 RCTs)
⊕⊕©©
low 1
Results in graphics
Adverse events
Beta-estradiol patch 0.05 or 0.1
mg/ day
vs CEE 0.625 or 1.25 mg/ day
Two studies reported data unsuit-
able for analysis. One reported
higher rates of breast pain and
vaginal bleeding in the 0.1 mg/
day beta-estradiol group than in
the placebo group. There was no
evidence of a dif ference between
other groups
711
(2 RCTs)
⊕©©©
very low 1,2
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
OR: odds rat io; CI: Conf idence interval; mg/ d: m illigrams per day
1 Downgraded two levels for very serious risk of bias: studies at high or unclear risk of bias in most domains. Findings
unreliable as no stat ist ical data suitable for analysis
2Downgraded one level for serious imprecision, with low event rate
2
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Oral beta-estradiol versus conjugated equine estrogen for hot f lushes
Population: women with hot f lushes
Setting: community
Intervention: oral beta-estradiol
Comparison: conjugated equine estrogen (CEE)
Outcomes Beta-estradiol versus CEE No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Frequency of hot f lushes
Oral beta-estradiol 1.0 and 2.0
mg/ day vs
CEE 0.625 or 1.25 mg/ day
One study with data unsuitable for
analysis reported no evidence of
a dif ference between the groups
102
(1 study)
⊕©©©
very low1,2
Adverse events
Oral beta-estradiol 1.0 or 2.0 mg/
day vs
CEE 0.625 or 1.25 mg/ day
One study reported no evidence of
a dif ference between the groups
(OR 1.20, 95%CI 0.50 to 2.87)
103
(1 RCT)
⊕©©©
very low3
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
OR: odds rat io; CI: Conf idence interval; mg/ d: m illigrams per day
1 Downgraded two levels for very serious risk of bias: studies at high or unclear risk of bias in most domains. Findings
unreliable as no stat ist ical data suitable for analysis
2Downgraded one level for serious imprecision, with small sample size
3Downgraded one level for very serious risk of bias (methods not adequately reported) and two levels for very serious
imprecision (low event rate and small sample size)
2
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D I S C U S S I O N
Summary of main results
This review assessed the effectiveness and safety of bio-identi-
cal hormones (beta-estradiol E2) compared to placebo, or non
bioidentical hormones for the relief of vasomotor symptoms dur-
ing the menopausal transition.
According to the findings of this systematic review, treatment with
oral and transdermal beta-estradiol is more effective in the relief
of menopausal hot flushes than placebo. There was no good ev-
idence of a difference in effectiveness between BHT and CEE
but the evidence was insufficient to reach a definite conclusion.
Even in extremely low doses, estrogen patches are more effective
than placebo in decreasing the number of daily hot flushes in
women experiencing at least seven hot flushes per day or 50 hot
flushes per week at baseline. Our findings suggest that, regardless
of the route of administration, low doses of BHT can reduce hot
flushes in these women. An advantage of the transdermal route,
compared to the oral route, is that it is available in many dif-
ferent forms and doses (Kopper 2009). In comparisons between
BHT and placebo, adverse events were more common in the in-
tervention arm. Breast tenderness (Archer 1992; de Vrijer 2000;
Speroff 1996; von Holst 2000) and vaginal bleeding (De Aloysio
2000; de Vrijer 2000; Good 1999; Notelovitz 2000a; Wiklund
1993) were the most commonly reported adverse effects among
estrogen users. Two trials reported one case of endometrial cancer
each in a woman using beta-estradiol (de Vrijer 2000; Notelovitz
2000b). Bleeding andbreast tendernessweremore frequent among
women using higher rather than lower doses of estrogen, regard-
less of the type of estrogen (Archer 1992). Adverse skin reac-
tions were most common among women using transdermal forms
of beta-estradiol or placebo (Bacchi-Modena 1997; De Aloysio
2000; Gordon 1995; Speroff 1996; Utian 1999; Wiklund 1993).
The most frequent side-effects were breast tenderness, headache
and skin reactions. The prevalence of these symptoms was related
to the dosages and routes of administration (Steingold 1991). Ac-
cording to the most recent U.S. Food and Drug Administration
(FDA) recommendation, hormonal therapy should be given at the
lowest effective dose for the least amount of time necessary for
women in the menopausal transition (NAMS 2012).
In comparisons between BHT and CEE, findings with regard to
adverse effects were inconsistent and the quality of the evidence
was too very low to reach any firm conclusions (Archer 1992;
Good 1999; Gordon 1995)
Subgroup analyses of comparisons between BHT and placebo sug-
gested that increased doses of BHT may be associated with in-
creased effectiveness but also increased risk of adverse effects.
Overall completeness and applicability of
evidence
This review identified 23 studies which evaluated bioidentical hor-
mones for postmenopausal women with amenorrhoea and ele-
vated FSH. Most of the trials included in this systematic review
followed participants only up to 12 weeks. This is a limitation
because these follow-up periods are too short to assess safety out-
comes such as those included in the WHI study. One of the stud-
ies (De Vrijer 2000) noted that five women in the intervention
grouped developed endometrial hyperplasia as no progestogens
were administered during the trial treatment in order to avoid any
effect of progestogens on the efficacy data. Studies with longer fol-
low-ups which include women who still have their uterus would
need to give participants progestogens ormicronised progesterone,
which is a bioidentical hormone used to prevent estrogen-related
endometrial hyperplasia (NAMS 2012; Furness 2012). Another
limitation of this systematic review is the lack of studies compar-
ing beta-estradiol combined with progesterone. This precludes us
from assessing if this type of prescription would alter the effects of
beta-estradiol.
Although we did not restrict study eligibility by severity of va-
somotor symptoms, the findings of this review apply largely to
women with moderate to severe hot flushes, since most of the
studies included only women with a minimum of three to seven
hot flushes per day or 56 to 60 hot flushes per week of moderate
to severe intensity.
The FDA 2003 recommends that to test the efficacy of treat-
ments for vasomotor symptoms, the mean change in symptoms
from baseline should be measured at four and 12 weeks. All stud-
ies included in this review followed this recommendation except
Gordon 1995 which performed measurements at 11 weeks. As
noted above, the limited follow-up in the included studies means
that no data were reported about the safety of BHT with regard to
long-term outcomes such as heart attack, stroke and breast cancer.
Quality of the evidence
Eight of 23 studies included in this review we deemed to be at
high risk of bias in one or more domains. Limitations included
very poor reporting of methods, attrition bias due to high or un-
balanced dropouts between groups, and other potential sources
of bias related to study design. Most studies were either funded
by industry or the funding source was not reported. Many of the
studies failed to report data suitable for analysis.
The overall quality of the evidence on the effect of beta-estradiol
ranged from very low to moderate. Common limitations were
risk of bias, inconsistency and imprecision. (Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3; Summary of findings 5; Summary of findings 7).
Unfortunately a large number of studies were not suitable for
pooling, in most cases due to skewed data associated with very
high standard deviations, and this limited the power of our meta-
analyses. However, the findings of studies with data unsuitable for
pooling supported the findings of pooled analyses.
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Potential biases in the review process
Wemade all efforts to identify relevant articles for this review by an
extensive electronic search and careful evaluation of study reports
for eligibility. Nevertheless, we cannot rule out the possibility that
we may have lost some trials not accessible to our search. This
review was limited because of the methodological heterogeneity of
the included studies. The incompleteness of some of the reports
and our difficulties in obtaining clarification of certain trial details
or in resolving ambiguities in the reports may have contributed to
some bias in their assessment. Duplicate study selection, data ex-
traction and quality assessment of the included studies minimised
the potential for additional bias beyond those detailed in the ’Risk
of bias in included studies’ tables.
Agreements and disagreements with other
studies or reviews
These results are consistent with other reviews and meta-analyses
of trials of transdermal beta-estradiol compared with placebo for
treating menopausal hot flushes (Corbelli 2014; Heidi 2004). The
intensity of symptoms was also significantly lower in all interven-
tion groups compared to placebo. Two studies compared transder-
mal beta-estradiol gel versus placebo (Archer 2003; Archer 2012).
In all sets of comparisons there was a significant difference favour-
ing the intervention group compared with placebo. Compared
with placebo, oral beta-estradiol produced statistically significant
improvements in hot flush frequency or severity, or both.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is low to moderate quality evidence that BHT in various
forms and doses is more effective than placebo in decreasing the
frequency of moderate to severe hot flushes in women in the
menopausal transition period. There was low to moderate quality
evidence of higher rates of adverse effects such as breast pain, skin
reactions, vaginal bleeding and headache in the BHT group. There
is some evidence to suggest that higher doses of BHT are more
effective but also associated with a higher risk of adverse effects.
Women with a uterus who are taking any form of estrogen require
co-administration of a progestogen, as unopposed estrogen is as-
sociated with endometrial hyperplasia (Furness 2012).
Therewas no good evidence of a difference in effectiveness between
BHT and CEE and findings with regard to adverse effects were
inconsistent. The quality of the evidence was too low to reach any
firm conclusions.
The main limitations in the quality of the evidence were study risk
of bias (mainly due to poor reporting of methods), imprecision
and lack of data suitable for analysis. No data are yet available
about the safety of BHT with regard to long-term outcomes such
as heart attack, stroke and breast cancer.
Implications for research
Studies that follow the guideline recommendations on hormone
therapy for the relief of vasomotor symptoms in women during
themenopausal transition (using the lowest effective dose through
the best route of administration) are needed to confirm the few
positive results that have been reported in randomised clinical tri-
als to date. The review did not provide sufficient evidence to offer
clinicians a firm conclusion as to the best dose and route of admin-
istration of bioidentical hormones (bioidentical estrogen alone or
in combination with progesterone) for treating women with vaso-
motor symptoms. Data from trials evaluated in this review do not
allow comparisons of adverse effects because they were reported in
incomplete and nonstandardised ways. The symptom treatment
trials reviewed herein enrolled small numbers of participants for
short periods of time and were inadequately designed to capture
important health outcomes reported by theWomensHealth Initia-
tive study (Rossouw 2002). Future trials could address these issues
by providing a broader demographic sample of women, longer fol-
low-up periods, larger numbers of participants, andmore head-to-
head comparisons of BHT (with or without progesterone) versus
equine products, estradiol valerate, micronised estradiol, estropi-
pate (piperazine estrone sulfate), ethinyl estradiol alone or in com-
binationwith various progestogens (medroxyprogesterone acetate,
norethindrone, norethindrone acetate, drospirenone, dienogest)
administered in cyclic or continuous regimens.
Research is needed to investigate the safety of BHT with regard to
long-term outcomes such as heart attack, stroke and breast cancer.
A C K N OW L E D G E M E N T S
We would like to thank the Cochrane Gynaecology and Fertility
group Editorial Team, mainlyMs. HelenNagels for their thought-
ful comments and suggestions, and Information Specialist Mar-
ian Showell. We also want to acknowledge Cristiane R Macedo
for assistance with developing the first search strategy and Evilásio
Rodrigues Cortes for the valuable technical help with the Review
Manager (RevMan) (RevMan 2014) programme.
31Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Archer 1992 {published data only}
Archer DR, Fischer LA, Rich D, Schade GH, Schwartz
S, Wittcoff H, et al. Estrace vs Premarin for treatment of
menopausal symptoms: dosage comparison study. Advances
in Therapy 1992;9:21–31.
Archer 2003 {published data only}
Archer DF. Percutaneous 17-estradiol gel for the treatment
of vasomotor symptoms in postmenopausal women. The
Journal of The North American Menopause Society 2003;10
(6):516–21. [DOI: 10.1097/01
Archer 2012 {published data only}
Archer DF, Pickar JH, MacAllister DC, Warren MP.
Transdermal estradiol gel for the treatment of symptomatic
postmenopausal women. Menopause 2012;19(6):622–9.
Bacchi-Modena 1997 {published data only}
Bacchi-Modena A, Bacchi-Modena C, Bolis P, Campagnoli
M, De Cicco R, Meschia G, et al. Efficacy and tolerability
of Estraderm MX, a new estradiol matrix patch. Maturitas
1997;27:285–92.
Buster 2008 {published data only}
Buster JE, Koltun WD, Pascual ML, Day WW, Peterson
C. Low-dose estradiol spray to treat vasomotor symptoms.
Obstetrics and Gynecology 2008;111:1343-51. CENTRAL:
CN–00640015]
Cohen 1999 {published data only}
Cohen L, Coxwell WL, Melchione T, Koltun W, Gibson
E, Gupta N, et al. Low-dose 17-beta estradiol matrix
transdermal system in the treatment of moderate-to-severe
hot flushes in postmenopausal women. Current Therapeutic
Research - Clinical and Experimental 1999;60(10):534–47.
De Aloysio 2000 {published data only}
De Aloysio D, Rovati LC, Giacovelli G, Setnikar I,
Bottiglioni F. Efficacy on climacteric symptoms and
safety of low dose estradiol transdermal matrix patches.
Azneimittelforschung 2000;50:293–300.
De Vrijer 2000 {published data only}
De Vrijer B, Snijders MP, Troostwijk AL, Thé RJ, Iding
Da Freise JM, Smit H, et al. Efficacy and tolerability of a
new estradiol delivering matrix patch (Estraderm MX) in
postmenopausal women. Maturitas 2000;34:47–55.
Good 1999 {published data only}
Good WR, John VA, Ramirez M, Higgins JE. Comparison
of Alora estradiol matrix transdermal delivery system
with oral conjugated equine estrogen therapy in relieving
menopausal symptoms. Climacteric 1999;2:29–36.
Gordon 1995 {published data only}
Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane
PJ, Schwenker CE. Efficacy and safety of a seven-day,
transdermal estradiol drug-delivery system: comparison
with conjugated estrogens and placebo. International
Journal of Fertility and Menopausal Studies 1995;40:126–34.
Haines 2009 {published data only}
Haines C, Yu SL, Hiemeyer F, Schaefers M. Micro-
dose transdermal estradiol for relief of hot flushes in
postmenopausal Asian women: a randomized controlled
trial. Climacteric 2009;12:419-26.
Honjo 2009 {published data only}
Honjo H, Taketani Y. Low-dose estradiol for climacteric
symptoms in Japanese women: a randomized, controlled
trial. Climacteric 2009;12:319-28. [DOI: 10.1080/
13697130802657888
Nielsen 2006 {published data only}
Nielsen TF, Ravn P, Pitkin J, Christiansen C. Pulsed
estrogen therapy improves postmenopausal quality of life:
a 2-year placebo-controlled study. Maturitas 2006;53:
184–90. [DOI: 10.1016
Notelovitz 2000a {published data only}
Notelovitz M, Lenihan JP, McDermott M, Kerber IJ,
Nanavati N, Arce J. Initial 17beta-estradiol dose for treating
vasomotor symptoms. Menopause 2000;7:310–17.
Notelovitz 2000b {published data only}
Notelovitz M, Mattox JH. Suppression of vasomotor and
vulvovaginal symptoms with continuous oral 17beta-
estradiol. Menopause 2000;7:310–317.
Rovati 2000 {published data only}
Rovati LC, Setnikar I, Genazzani AR. Dose-response
efficacy of a new estradiol transdermal matrix patch for 7-
day application: a randomized, double-blind, placebo-
controlled study. Menopause: The Journal of The North
American Menopause Society 2002;22(1):114–21. [DOI:
10.1097
Simon 2006 {published data only}
Simon JA. Estradiol in micellar nanoparticles: the efficacy
and safety of a novel transdermal drug-delivery technology
in the management of moderate to severe vasomotor
symptoms. Menopause: The Journal of The North American
Menopause Society 2006;13(2):222–31. DOI: 10.1097/
01.gme.0000174096.56652.4f ]
Simon 2007 {published data only}
Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski
J, Snabes MC. Low dose of transdermal estradiol gel for
treatment of symptomatic postmenopausal women: a
randomized controlled trial. Obstetrics and Gynecology
2007;109(3):588–96.
Speroff 1996a {published data only}
Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA,
Paulissen JB, Rowan JP. Efficacy and local tolerance of a
low-dose, 7-day matrix estradiol transdermal system in the
treatment of menopausal vasomotor symptoms. Obstetrics
and Gynecology 1996;88(4):587–92.
Speroff 1996b {published data only}
Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA,
Paulissen JB, Rowan JP. Efficacy and local tolerance of a
low-dose, 7-day matrix estradiol transdermal system in the
32Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
treatment of menopausal vasomotor symptoms. Obstetrics
and Gynecology 1996;88(4):587–92.
Utian 1999 {published data only}
Utian WH, Burry KA, Archer DF. Efficacy and safety of
low, standard, and high dosages of an estradiol transdermal
system (Esclim) compared with placebo on vasomotor
symptoms in highly symptomatic menopausal patients.
American Journal of Obstetrics and Gynecology 1999;181:
71–9.
von Holst 2000 {published data only}
von Holst T, Sallbach B. Efficacy and tolerability of a
new 7-day transdermal estradiol patch versus placebo in
hysterectomized women with postmenopausal complaints.
Maturitas 2000;34:143–53.
Wiklund 1993 {published data only}
Wiklund I, Karlberg J, Mattsson LA. Quality of life of
postmenopausal women on a regimen of transdermal
estradiol therapy: a double-blind placebo-controlled study.
American Journal of Obstetrics and Gynecology 1993;168:
824–30.
References to studies excluded from this review
Akhila 2006 {published data only}
Akhila V, Pratapkumar. A comparison of transdermal and
oral HRT for menopausal symptom control. International
Journal of Fertility and Women’s Medicine 2006;51(2):64–9.
Bachmann 2003 {published data only}
Bachmann GA. Estrogen no matter how delivered relieves
postmenopausal vasomotor symptoms. Menopause 2003;10
(6):494–6.
Bachmann 2007 {published data only}
Bachmann GA, Schaefers M, Uddin A, Utian WH.
Lowest effective transdermal 17-estradiol dose for relief
of hot flushes in postmenopausal women. Obstetrics and
Gynecology 2007;110(4):771-9.
Bachmann 2008 {published data only}
Bachmann GA, Schaefers M, Uddin A, Utian WH. What’s
the lowest effective estrogen dose for hot flushes?. Journal of
Family Practice 2008;57(1):9.
Ben-Chetrit 2005 {published data only}
Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, Zacut
D, Shimonovitz S, Gelber H, et al. Vaginal ring delivering
estradiol and progesterone: a possible alternative to relieve
climacteric symptoms. Israeli Medical Association Journal
2005;7:302–6.
Carranza-Lira 2006 {published data only}
Carranza-Lira S, Gooch AL, Velasco-Díaz G, Solano J,
Arzola-Paniagua A. Low and ultra low-dose estrogen therapy
for climacteric symptom control - preliminary report.
International Journal of Fertility and Women’s Medicine 2006;
51(4):171–5.
Castelo-Branco 2010 {published data only}
Castelo-Branco C, Coloma JL. The role of intranasal
estradiol spray in the management of moderate to severe
vasomotor symptoms in menopausal women. Gynecological
Endocrinology 2010;26(1):23–9. [DOI: 10.3109/
09513590903159698
Chung 1996 {published data only}
Chung TKH, Yip SK, Lam P, Chang AMZ, Haines CJ. A
randomized, double-blind, placebo-controlled, crossover
study on the effect of oral oestradiol on acute menopausal
symptoms. Maturitas 1996;25:115–23.
Conaway 2011 {published data only}
Conaway E. Bioidentical hormones: an evidence-based
review for primary care providers. Journal of the American
Osteopathic Association 2011;111(3):153–64.
Cortes-Bonilla 2015 {published data only}
Cortés-Bonilla M, Bernardo-Escudero R, Alonso-Campero
R, Francisco-Doce MT, Hernández-Valencia M, Celis-
González C, et al. Treatment of menopausal symptoms
with three low-dose continuous sequential 17β-estradiol/
progesterone parenteral monthly formulations using novel
non-polymeric microsphere technology. Gynecological
Endocrinology 2015;10:1–8.
Darj 1991 {published data only}
Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and
endometrial effects of oestradiol and progesterone in post-
menopausal women. Maturitas 1991;13(2):109–15.
Diem 2006 {published data only}
Diem S, Grady D, Quan J, Vittinghoff E, Wallace R, Hanes
V, et al. Effects of ultra low-dose transdermal estradiol
on postmenopausal symptoms in women aged 60 to 80
years. Menopause 2006;13(1):130–8. [DOI: 10.1097/
01.gme.0000192439.82491.24
Ettinger 2007 {published data only}
Ettinger B. Rationale for use of lower estrogen doses for
postmenopausal hormone therapy. Maturitas 2007;57(1):
81–4.
Files 2011 {published data only}
Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy.
Mayo Clinic Proceedings 2011;86(7):673.
Formby 2011 {published data only}
Formby B, Schmidt F. Efficacy of biorhythmic transdermal
combined hormone treatment in relieving climacteric
symptoms: a pilot study. International Journal of General
Medicine 2011;4:159–63.
Ganz 2002 {published data only}
Ganz P. Vasomotor and vascular effects of hormone
replacement therapy. American Journal of Cardiology 2002;
90:F11–16. PUBMED: 12106634]
Gass 2004 {published data only}
Gass MS, Rebar RW, Cuffie-Jackson C, Cedars MI, Loboe
RA, Shoupe D, et al. A short study in the treatment of
hot flashes with buccal administration of 17- estradiol.
Maturitas 2004;49:140–7.
Hedrick 2009 {published data only}
Hedrick RE, Ackerman RT, Koltun WD, Halvorsen
MB, Lambrecht LJ. Transdermal estradiol gel
0.1% for the treatment of vasomotor symptoms in
postmenopausal women. The Journal of The North American
33Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Menopause Society 2009;16(1):132–40. [DOI: 10.1097/
gme.0b013e31817d5372
Iftikhar 2011 {published data only}
Iftikhar S, Shuster LT, Johnson RE, Jenkins SM, Wahner-
Roedler DL. Use of bioidentical compounded hormones for
menopausal concerns: cross-sectional survey in an academic
menopause center. Journal of Women’s Health 2011;20(4):
559–65. [DOI: 10.1089
Jensen 1987 {published data only}
Jensen PB. Climacteric symptoms after oral and
percutaneous hormone replacement therapy. Maturitas
1987;9:207–15.
Lacut 2004 {published data only}
Lacut K, et al. Effects of oral and transdermal 17 beta-
estradiol combined with progesterone on homocysteine
metabolism in postmenopausal women: a randomised
placebo-controlled trial. Atherosclerosis 2004;174(1):173-
80. PUBMED: 15135267]
Lindh 2004 {published data only}
Lindh-Åstrand L, Nedstrand E, Wyon Y, Hammar M.
Vasomotor symptoms and quality of life in previously
sedentary postmenopausal women randomised to physical
activity or estrogen therapy. Maturitas 2003;48:97–105.
Lopes 2000 {published data only}
Lopes P, Merkus HM, Nauman J, Bruschi F, Foidart
JM, Calaf J. Randomized comparison of intranasal and
transdermal estradiol. Obstetrics and Gynecology 2000;96
(6):906–12.
Lubbert 1997 {published data only}
Lübbert H, Nauert C. Continuous versus cyclical
transdermal estrogen replacement therapy in
postmenopausal women: influence on climacteric
symptoms, body weight and bleeding pattern. Maturitas
1997;28:117-25.
MacLennan 2009 {published data only}
MacLennan AH. Evidence-based review of therapies at
the menopause. International Journal of Evidence Based
Healthcare 2009;7:112–23. [DOI: 10.1111
Marslew 1991 {published data only}
Marslew U, Riis B, Christiansen C. Progestogens:
therapeutic and adverse effects in early post-menopausal
women. Maturitas 1991;13(1):7–16.
Marslew 1994 {published data only}
Marslew U, Munk-Nielsen N, Nilas L, Riis BJ, Christiansen
C. Bleeding pattern and climacteric symptoms during
different sequential combined HRT regimens in current
use. Maturitas 1994;19(3):225–37.
Mather 2000 {published data only}
Mather KJ, Norman EG, Prior JC, Elliott TG. Preserved
forearm endothelial responses with acute exposure to
progesterone: a randomized cross-over trial of 17-b
estradiol, progesterone, and 17-b estradiol with progesterone
in healthy menopausal women. The Journal of Clinical
Endocrinology and Metabolism 2000;85(12):4644-49.
Mirkin 2015 {published data only}
Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF.
17(beta)-Estradiol and natural progesterone for menopausal
hormone therapy: REPLENISH phase 3 study design of a
combination capsule and evidence review. Maturitas 2015;
81(1):28–35.
Mizumuna 2011 {published data only}
Mizunuma H. Clinical usefulness of a low-dose maintenance
therapy with transdermal estradiol gel in Japanese women
with estrogen deficiency symptoms. Climacteric 2011;14:
581-89. CENTRAL: CN–00806509]
Odabasi 2007 {published data only}
Odaba i AR, Yüksel H, Demircan SS, Kaçar DF, Çulhaci
N, Özkara EE. A prospective randomized comparative study
of the effects of intranasal and transdermal 17ß estradiol on
postmenopausal symptoms and vaginal cytology. Journal of
Postgraduate Medicine 2007;53:221–7.
Panay 2007 {published data only}
Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-
low-dose estradiol and norethisterone acetate: effective
menopausal symptom relief. Climacteric 2007;10:120–31.
Pélissier 2001 {published data only}
Pélissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol
F, Jondet M. Chlormadinone acetate versus micronized
progesterone in the sequential combined hormone
replacement therapy of the menopause. Maturitas 2001;40
(1):85–94.
Rosano 2000 {published data only}
Rosano GMC, Webb CM, Chierchia S, Morgani GL,
Gabraele M, Sarrel PM, et al. Natural progesterone, but
not medroxyprogesterone acetate, enhances the beneficial
effect of estrogen on exercise-induced myocardial ischemia
in postmenopausal women. Journal of the American College
of Cardiology 2000;36(7):2154–9.
Ryan 2001 {published data only}
Ryan N, Rosner A. Quality of life and costs associated with
micronized progesterone and medroxyprogesterone acetate
in hormone replacement therapy for nonhysterectomized,
postmenopausal women. Clinical Therapeutics 2001;23(7):
1099-1115. [DOI: 10.1016
Serfaty 2003 {published data only}
Serfaty D, Reilhac P, Eschwege E, Ringa V, Blin P, Nandeuil
A, et al. Compliance with hormone replacement therapy
in menopausal women: results of a two-year prospective
French study comparing transdermal treatment with fixed
oral combination therapy [Observance du traitement
hormonal substitutif de la ménopause: résultats d’une étude
prospective française de deux ans, comparantun traitement
transdermique et une association fixe par voie orale].
Gynécologie Obstétrique and Fertilité 2003;31:525-33.
Sitruk 2007 {published data only}
Sitruk-Ware R. Routes of delivery for progesterone and
progestins. Maturitas 2007;57:77-80.
34Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Siyam 2013 {published data only}
Siyam T, Yuksel N. Beliefs about bioidentical hormone
therapy: a cross-sectional survey of pharmacists. Maturitas
2013;74:196–202.
Skarsgard 2000 {published data only}
Skarsgard C, Berg GE, Ekblad S, Wiklund I, Hammar ML.
Effects of estrogen therapy on well-being in postmenopausal
women without vasomotor complaints. Maturitas 2000;36:
123–30.
Somunkiran 2007 {published data only}
Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect
of tibolone versus 17-estradiol on climacteric symptoms in
women with surgical menopause: a randomized, cross-over
study. Maturitas 2007;56:61–8.
Sood 2011 {published data only}
Sood R, Shuster L, Smith R, Vincent A, Jatoi A. Counseling
postmenopausal women about bioidentical hormones: ten
discussion points for practicing physicians. Journal of the
American Board of Family Medicine 2011;24(2):202-10.
Sood 2013 {published data only}
Sood R, Warndahl RA, Schroeder DR, Singhd R J, Rhodes
DJ, Wahner-Roedlerf D, et al. Bioidentical compounded
hormones: a pharmacokinetic evaluation in a randomized
clinical trial. Maturitas 2013;74:375- 82.
Studd 1999 {published data only}
Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos
Y, et al. Efficacy and acceptability of intranasal 17 -
oestradiol for menopausal symptoms: randomised dose-
response study. Lancet 1999;353:1574–8.
Suvanto-luukkonen 1997 {published data only}
Suvanto-Luukkonen E, Sundstrijm E, Jorma Penttinen J,
Läärä E, Pramila S, Kauppila A. Percutaneous estradiol
gel with an intrauterine levonorgestrel releasing device or
natural progesterone in hormone replacement therapy.
Maturitas 1997;26:211–17.
Vartiainen 1993 {published data only}
Vartiainen J, Wahlstriim T, Nilsson CG. Effects and
acceptability of a new 17B-oestradiol releasing vaginal ring
in the treatment of postmenopausal complaints. Maturitas
1993;17:129–37.
Veerus 2013 {published data only}
Veerus P, Hovi SL, Sevón T, Hunter M, Hemminki E. The
effect of hormone therapy on women’s quality of life in
the first year of the Estonian Postmenopausal Hormone
Therapy trial. Menopause 2013;20(3):291–8. [DOI:
10.1097/GME.0b013e31826ce3ed.
Whelan 2013 {published data only}
Whelan AM, Jurgens TM, Trinacty M. Bioidentical
progesterone cream for menopause-related vasomotor
symptoms: is it effective?. The Annals of Pharmacotherapy
2013;47:112–6. [DOI: 10.1345
Wihlbacka 2005 {published data only}
Wihlbäck A, Nyberg S, Bäckström T, Bixo M, Sundstrom-
Poromaa I. Estradiol and the addition of progesterone
increase the sensitivity to a neurosteroid in postmenopausal
women. Psychoneuroendocrinology 2005;30(1):38–50.
Wolfe 1994 {published data only}
Wolfe BM, Plunkettb ER. Early effects of continuous low-
dosage dl-norgestrel administered alone or with estrogen.
Maturitas 1994;18:207–19.
Yesildaglar 2004 {published data only}
Yesildaglar N, Erkaya S, Uygur D, Göl K, Bingöl B, Günenç
Z. Efficacy of pulsed estrogen therapy in relatively younger
patients with surgically induced menopause. Human
Reproduction 2004;19(1):210–3.
Additional references
Adams 2001
Adams C, Cannell S. Women’s beliefs about “natural”
hormones and natural hormone replacement therapy.
Menopause 2001;8:433–40.
Cagnacci 2002
Cagnacci A, Arangino S, Tuveri F, Paoletti AM, Volpe A.
Regulation of the 24h body temperature rhythm of women
in luteal phase: role of gonadal steroids and prostaglandins.
Chronobiology International Journal 2002;19(4):721–30.
Corbelli 2014
Corbelli J, Shaikh N, Wessel C, Hess R. Low-dose
transdermal estradiol for vasomotor symptoms: a systematic
review. Menopause: The Journal of The North American
Menopause Society 2014;22(1):114–21. [DOI: 10.1097/
gme.0000000000000258
Corson 1993
Corson SL. A decade of experience with transdermal estrogen
replacement therapy: overview of key pharmacologic and
clinical findings. International Journal of Fertility 1993;38:
79–81.
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Drisko 2000
Drisko JA. Natural isomolecular hormone replacement: an
evidence-based medicine approach. International Journal of
Pharmaceutical Compounding 2000;4:414–20.
EMEA 2005
European Medicines Agency. Guideline on clinical
investigation of medicinal products for hormone
replacement therapy of oestrogen deficiency symptoms in
postmenopausal women. ema.europa.eu/ema/ Accessed
September 2012.
ES 2006
Endocrine Society. Bioidentical hormones: position
statement. endo-society.org/advocacy/policy/upload/
BH position Statement final 10 25 06 w Header.pdf
Accessed May 20, 2012.
FDA 2003
US Department of Health and Human Services. Guidance
for industry: estrogen and estrogen/progestin drug
35Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
products to treat vasomotor symptoms and vulvar
and vaginal atrophy symptoms-recommendations
for clinical evaluation. fda.gov/cder/guidance/
index.htm January 2003. [fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
ucm071643.pdf(accessed 2014 july ) ]
Freedman 2001
Freedman RR. Physiology of hot ashes. American Journal
of Human Biology 2001;13:453.
Freedman 2006
Freedman RR, Benton MD, Genik II RJ, Graydon FX.
Cortical activation during menopausal hot flashes. Fertility
and Sterility 2006;85:674.
Furness 2012
Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone
therapy in postmenopausal women and risk of endometrial
hyperplasia. Cochrane Database of Systematic Reviews 2012,
Issue 8. [DOI: 10.1002/14651858; CD000402
GRADEpro GDT 2015 [Computer program]
McMaster University (developed by Evidence Prime, Inc).
Available from gradepro.org. GRADEpro Guideline
Development Tool. McMaster University (developed by
Evidence Prime, Inc). Available from gradepro.org, 2015.
Harlow 2012
Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW,
et al. Executive summary of the Stages of Reproductive
Aging Workshop D10: addressing the unfinished agenda of
staging reproductive aging. Journal of Clinical Endocrinology
and Metabolism 2012;97(4):1159–68.
Heidi 2004
Heidi DN. Commonly used types of postmenopausal
estrogen for treatment of hot flashes. JAMA 2004;219(13):
1610–20. [DOI: 10.1001/jama.291.13.1610
Hersh 2003
Hersh AL, Stefanick ML, Stafford RS. National use of
postmenopausal hormone therapy: annual trends and
response to recent evidence. JAMA 2004;291:47–53.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2011a
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Higgins 2011b
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter
16: Special topics in statistics. In: Higgins JPT, Green
S (editors),Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Hilditch 1996
Hilditch JR, Lewis J, Peter A, VanMaris B, Ross A, Franssen
E, et al. A menopause-specific quality of life questionnaire:
development and psychometric properties. Maturitas 1996;
24(3):161–75.
Hunter 1992
Hunter MS. Women’s Health Questionnaire: a measure
of mid-aged women’s perceptions of their emotional and
physical health. Psychology and Health 1992;7(1):45–54.
Kaufert 1998
Kaufert P, Boggs PP, Ettinger B, Woods NF, Utian WH.
Women and menopause: beliefs, attitudes, and behaviours.
Menopause 1998;5:197.
Kopper 2009
Kopper NW, Gudeman J, Thompson DJ. Transdermal
hormone therapy in postmenopausal women: a review of
metabolic effects and drug delivery technologies. Journal of
Drug Design Development and Therapy 2009;6(2):193–202.
[PUBMED: 19920906 ]
Kronnenberg 1992
Kronnenberg F, Barnard RM. Modulation of menopausal
hot flashes by ambient temperature. Journal of Thermal
Biology 1992;17:43.
Lethaby 2013
Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden
J, Brown J. Phytoestrogens for menopausal vasomotor
symptoms. The Cochrane Library 2013;12:CD001395.
[DOI: 10.1002/14651858
NAMS 2012
North American Menopause Society. Hormone therapy
position statement of The North American Menopause
Society. The Journal of The North American Menopause
Society 2012;19(3):257–71.
Nelson 2006
Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller
J, et al. Nonhormonal therapies for menopausal hot flashes:
systematic review and meta-analysis. JAMA 2006;295(17):
2057–69.
Nielsen 2004
Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen
C. Pulsed estrogen therapy in prevention of postmenopausal
osteoporosis. A 2-year randomized, double blind, placebo-
controlled study. Osteoporosis International 2004;15(2):
168–74.
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, Cochrane. Review Manager
(RevMan). Version 5.3. Copenhagen: The Nordic
Cochrane Centre, Cochrane, 2014.
Rossouw 2002
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ,
Kooperberg C, Stefanick ML, et al. Risks and benefits of
estrogen plus progestin for healthy postmenopausal women.
JAMA 2002;288:321–33.
36Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rossouw 2013
Rossouw JE, Manson JE, Kaunitz AM, Anderson GL.
Lessons learned from the Women’s Health Initiative trials
of menopausal hormone therapy. Obstetrics and Gynecology
2013;121(1):172–6.
Seidl 1998
Seidl MM, Stewart DE. Alternative treatments for
menopausal symptoms: qualitative study of women’s
experiences. Canadian Family Physician 1998;44:1271–6.
Shifren 2007
Shifren JL, Desindes S, McIlwain M, Doros G, Mazer
NA. A randomised, open-label, crossover study comparing
the effects of oral versus transdermal estrogens therapy on
serum androgens, thyroid hormones, and adrenal hormones
in naturally menopausal women. Menopause 2007;14:985.
Shifren 2010
Shifren JL, Schiff I. Role of hormone therapy in the
management of menopause. Obstetrics and Gynecology
2010;115(4):839–55.
Speroff 2011
Speroff L, Glass RH, Kase NG, editors. Clinical
Gynecologic Endocrinology and Infertility. Clinical
Gynecologic Endocrinology and Infertility. 8th Edition.
Philadelphia, PA: Lippincott Williams & Wilkins, 2011.
Steingold 1991
Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin
M, Reznikov S. Comparison of transdermal to oral estradiol
administration on hormonal and hepatic parameters in
women with premature ovarian failure. Journal of Clinical
Endocrinology and Metabolism 1991;73:275–80.
Sturdee 2011
Sturdee DW, Pines A, on behalf of the International
Menopause Society Writing Group. Updated IMS
recommendations on postmenopausal hormone therapy
and preventive strategies for midlife health. Climacteric
2011;14:202–20.
Tartaryn 1981
Tartaryn IV, Lomax P, Meldrum DR, Bajorek JG, CHesorek
W, Judd HL. Objective techniques for the assessment of
menopausal hot flushes. Obstetrics and Gynecology 1981;57:
340–4.
Wilkin 1981
Wilkin JR. Flushing reactions: consequences and
mechanisms. Annals of Internal Medicine 1981;95:468.
References to other published versions of this review
Gaudard 2013
Gaudard AMIS, da Silva EMK, Silva de Souza S, Torloni
MR, Macedo CR. Bioidentical hormones for women with
hot flushes. Cochrane Database of Systematic Reviews 2013,
Issue 2. [DOI: 10.1002/14651858.CD010407
∗ Indicates the major publication for the study
37Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Archer 1992
Methods Multicenter, double-blind, randomised, placebo-controlled trial
Number of centres: 7 USA
Number of women randomised: 128
Number of women analysed: 100
Withdrawals and losses to follow-up: n = 21.9 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Menopausal status: peri- and post-menopausal
Age: mean 50.6 years, SD 5.9
Ethnicity: not stated
Inclusion criteria: healthy, natural or surgically post-menopausal women, FSH > 40 IU/
mL and serumoestradiol < 30 pg/mL (surgical menopause only), age 40-60 years (natural
menopause only), moderate severe vasomotor symptoms (> 5/day of moderate to severe
intensity)
Exclusion criteria: significant past or present illness, genitourinary symptoms, psycho-
logical symptoms, gastrointestinal conditions, chronic headaches, any contraindications
to beta-estradiol usage, HT within 3 months, concomitant medications that may affect
study parameters, alcohol or drug abuse, laboratory abnormalities, Pap smear dysplasia,
endometrial hyperplasia
Confirmation of ovarian failure: FSH > 40 IU/mL and serum oestradiol < 30 pg/mL
(surgical menopause only)
Baseline equality: not reported for vasomotor symptoms. Groups equal for age, age at
menopause, weight, history of HRT and history of abnormal Pap smear
Baseline Symptoms: all women had moderate-severe vasomotor symptoms at baseline
(inclusion criteria)
Interventions Oral micronised beta-estradiol 1 or 2 mg/d versus conjugated equine estrogen (CEE) 0.
625 or 1.25 mg/d or placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events whether reported by the patient
Notes Data unsuitable for analysis: reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not reported
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Archer 1992 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported ”double-blind“. No further de-
tails
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses: 28/128 = 22%. Intention-to-treat
analysis: no
Selective reporting (reporting bias) Low risk The study protocol was not available but it
is clear that the published reports included
all expected outcomes, including those that
were pre-specified
Other bias Low risk The study appears to be free of other
sources of bias
Archer 2003
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 11 in USA
Number of women randomised: 221
Number of women analysed: 196
Statistical analysis: baseline characteristics were compared among treatment groups with
analysis of variance for continuous variables and the Cochrane-Mantel-Haenszel test
and Fisher exact test for categorical variables. The primary efficacy variable was analysed
using analysis of covariance and Dunnett’s test for multiple comparisons. The incidence
of adverse events was compared between active gel dose groups and the placebo group
using Pearson X 2 test and a multiple comparisons procedure. All statistical tests were
two-sided with an alpha of 0.049. Where multiple comparisons were used, the overall
alpha level was 0.049
Withdrawals and losses to follow-up: n = 25. Only 4 of these women (1.8%) withdrew
because of adverse events
Duration of trial: 12 weeks
Conflict of interest: none declared
Participants Inclusion criteria: healthy postmenopausal women who were amenorrhoeic either nat-
urally (for at least 6 months) or surgically (with bilateral oophorectomy), had a serum
estradiol concentration no greater than 20 pg/mL, a serum FSH level of at least 40 mIU/
mL, and had a minimum of seven hot flushes per day or 60 hot flushes per week of
moderate-to-severe intensity (i.e. that interfered with daily activities, disrupted sleep, or
were associated with perspiration)
Exclusion criteria: treatment with oral, transdermal, or vaginal steroid hormones (estro-
gens, progestogens, androgens, or corticosteroids) at any time during the 8 weeks before
the first screening visit or any of the following: allergy to estradiol; reactions to transder-
mally administered medications; beta-estradiol-dependent neoplasia; vascular disease,
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Archer 2003 (Continued)
thrombotic disorders, angina, active hepatic or gallbladder disease during the prior 6
months; or undiagnosed vaginal bleeding during the prior 6 months
Interventions 221 women were randomised to one of three gel groups: a) 1.25 g/day beta-estradiol gel
containing 0.75 mg of estradiol (n = 75), b) 2.5 g/day beta-estradiol gel containing 1.5
mg estradiol (n = 73), or c) placebo gel (n = 73). The placebo gel was packaged to have
an identical appearance to the beta-estradiol gel. The gel was applied once daily on the
arm using a dispenser
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Diaries reviewed at weeks 4, 8, and 12 for incidence of adverse events
Notes Treatment groups were comparable at baseline, except for mean weight which was sig-
nificantly higher in the 1.25 g/day beta-estradiol gel group
Data for effectiveness skewed; findings reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported. Authors only reported that
”Eligible women were randomly assigned
to one of three treatment groups...“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported that ”The placebo gel was
packaged to have an identical appearance
to the 17-estradiol gel“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses 25/221 (11.3%). No ITT analysis
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Other bias Low risk No other source of potential bias detected
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Archer 2012
Methods Multicentre, double-blind, randomised, placebo-controlled trial, phase 4 study
Number of centres: 78 sites in the USA
Number of women randomised: 351
Number of women analysed: 277
Statistical analysis: a sample size of 110 per group was estimated for the phase 4 study
based on (1) a SD of 4.5 and a change of 2 for average daily moderate to severe hot
flushes, (2) a SD of 0.72 and a change of 0.3 in hot flush severity score, and (3) a dropout
rate of 12%, which would provide 80% power to reject the null hypothesis at weeks 4
and 12. A two-way analysis of covariance with fixed factors of treatment and centre and
baseline value as a covariate was used to determine significant differences
Withdrawals and losses to follow-up: n = 74 (21,1%). 12 withdrawn because of adverse
events
Duration of trial: 12 weeks
Conflict of interest: none declared
Participants Inclusion criteria: women who experienced at least an average of 7 moderate to severe
hot flushes per day or at least 50 moderate to severe hot flushes per week during the 2-
week screening period. Participants had serum estradiol concentrations of 20 pg/mL or
less and FSH levels of 40 mIU/mL or higher in both studies at screening
Exclusion criteria: known hypersensitivity to estrogens or contraindications to estrogen
therapy; endometrial biopsy at study entry interpreted as hyperplasia; abnormal Papani-
colaou test findings; body weight exceedingmore than130% of the ideal range for weight
and height or BMI of 39 kg/m2 or higher; uncontrolled hypertension; history of clini-
cally significant migraines, cerebrovascular disease, thromboembolic events, or coronary
heart disease or events; diabetes; liver disease; undiagnosed vaginal bleeding; malignancy
of the cervix, uterus, adrenal glands, pituitary glands, breast, or ovaries; or melanoma or
other skin cancers at an advanced stage. Treatments not permitted in the phase included
a current intrauterine device; oral, transdermal, or vaginal steroid hormones (estrogens,
progestogens, androgens, or natural remedies with hormonal effects); or selective es-
trogen receptor modulators within the last 30 days of screening; intrauterine progestin
implant within 60 days; or oral contraceptives, gonadotropins, anti-estrogens, chronic
high doses of corticosteroids, or thyroid medication not yet stabilised within 90 days
Interventions 0.375 mg beta-estradiol (1.25 g estradiol gel 0.03%), the expected no-effect dose of 0.
27 mg estradiol (0.9 g estradiol gel 0.03%), versus placebo gel
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events were recorded at each study visit
Notes The objective of this report was to compare the efficacy and safety of two doses (1.5
and 0.75 mg beta-estradiol) of a transdermal estradiol gel from a phase 3 study (Archer
2003) and two lower doses (0.375 and 0.27 mg beta-estradiol) from a phase 4 study (
Archer 2012), to determine the lowest practical dose for the treatment of postmenopausal
symptom and severity of hot flushes and vaginal cytology (vaginal maturation index)
SDsnot reported butwhen imputed, data for effectivenesswere skewed; findings reported
in an additional table
Risk of bias
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Archer 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors only reported that ”Eligible
women were randomised..“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors only reported ”...double-blind...
“No further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Authors only reported ”...double-blind...
“No further details
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses 74/351 (21.1%). ITT analysis
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Other bias Unclear risk Standard deviations not reported. No other
source of potential bias detected
Bacchi-Modena 1997
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 11 in Italy
Number of women randomised: 109
Number of women analysed: 98
Statistical analysis: analysis of covariance (ANCOVA) with baseline value as covariate
and treatment and centre as further effects in the model was used for the primary
efficacy variable as well as for all secondary variables. For tests on treatment differences
a significance level of 5% (two-sided) was applied
Withdrawals and losses to follow-up: n = 11; 5 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Healthy female outpatients, requiring treatment for climacteric symptoms,were required
to be at least 8 months after their last natural menstrual cycle or at least 6 weeks post-
oophorectomy
Inclusion Criteria: a minimum mean number of 7 moderate to severe hot flushes per 24
h during the last 2 weeks of a 4-week run-in period. Baseline serum FSH concentrations
> 50 IU and serum E2 concentrations < 20 pg/mL
Exclusion criteria: women who had received oral HT within 8 weeks, transdermal HT
within 4 weeks or vaginal estrogen within 6 weeks before the start of trial treatment
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Bacchi-Modena 1997 (Continued)
Interventions Transdermal beta-estradiol 0.05 mg/d versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse experiences were assessed by direct questioning.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors only reported double blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses 11/109 ( 10%). ITT analysis
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Other bias Unclear risk Standard deviations not reported. These
were imputed by the review authors
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Buster 2008
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 43 in USA
Number of women randomised: 458
Number of women analysed: 454
Statistical analyses were performed using SAS 8.2 (SAS Institute Inc., Cary, NC) on a
PC platform. Statistical tests to evaluate treatment differences were two-tailed, with a
significance level of 5% (0.05), and were declared statistically significant if the calculated
P value was 0.05 or less. Treatment by region interaction analyses were performed at
the 0.10 level. Adverse event terms were coded in Medical Dictionary for Regulatory
Activities Version 7.1 in a one-way analysis of variance
Duration of trial: 12 weeks
Withdrawals and losses to follow-up: n = 81, 12 because of adverse events
Conflict of interest: not stated
Participants Participants were naturally or surgically postmenopausal women aged 35 years or older
who were healthy, with an average of at least 8 moderate to severe hot flushes per day
(56 or more per week)
Inclusion Criteria: 12months of spontaneous amenorrhoea or 6months of amenorrhoea
with serum FSH levels more than 40 IU/L or at least 6 weeks after, surgical bilateral
oophorectomy with or without hysterectomy. Pap test with no dysplastic or malignant
cells, screening mammogram and breast examination with no masses or other findings
suspicious of malignancy, and endometrial biopsies showing no hyperplasia or cancer in
women with a uterus
Exclusion criteria: known hypersensitivity or known reaction to estrogens or progestins;
clinically relevant disease thatmight preclude safe participation; use of progestin implants
or injectable drug therapy or estrogen injectable or pellet therapy within 1 year, BMI
more than 35 kg/m2; uncontrolled hypertension (diastolic blood pressure 95 mmHg or
more and/or systolic blood pressure 180 mmHg or more); clinically relevant triglyceride
levels 3.4 mmol/L or more (300 mg/dL or more); documented history of coagulopathy,
thrombophlebitis, thrombosis, or thromboembolic disorders; history of cutaneous con-
tact allergy to adhesives, cosmetics, or topical medications, including sunscreens; abnor-
mal genital bleeding; and current dermatologic disease
Interventions Beta-estradiol nasal spray 0.021 mg/d, 0.029 mg/d, and 0.040 mg/d for the one-, two-,
and three-spray doses, respectively versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events were reported by the participant
Notes Study author reported only a washout period ”.. from estrogen-containing medications
before baseline assessments...“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study authors reported ”The women were
randomly assigned to treatment groups us-
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Buster 2008 (Continued)
ing a computer-generated central random-
ization schedule ...“
Allocation concealment (selection bias) Low risk Study authors reported ”...and the applica-
tor number was assigned through an inter-
active voice response system...“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study authors reported ”All study site per-
sonnel and the participants were blinded as
to the participant’s treatment group (active
or placebo)...“, ”Applicators containing E2
or placebo were identical in appearance...“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 81/454 (17%) losses in the intervention
group and unbalanced with control groups
No ITT
Selective reporting (reporting bias) Low risk All expected outcomes and all outcomes
listed in the protocol were reported
Other bias Low risk The study appears to be free of other
sources of bias
Cohen 1999
Methods Multicentre double-blind, randomised, placebo-controlled trial
Number of centres: 9 in USA
Number of women randomised: 259
Number of women analysed: 242
Statistical analysis: for primary outcomes the authors used an analysis of covariance
model including treatment and centre as factors and centralised baseline as a covariate.
Treatment-by-baseline and treatment-by-centre interaction terms were included in the
model. Student t-tests were performed using an alpha = 0.05 level of significance to assess
the difference in least significant means between intervention and control
Withdrawals and losses to follow-up: 15 (6%) (5 receiving active treatment, 10 receiving
placebo),14 participants (5 receiving active treatment, 9 receiving placebo) did not meet
protocol criteria (participant’s diary recorded during the run-in period did not show 10
days of moderate-severe flushes), 1 patient receiving placebo used proscribed medication
(oral beta-estradiol)
Conflict of interest: none declared
Participants Healthy, postmenopausal women aged 35 years or older
Inclusion criteria: a minimum of 7 hot flushes per 24 hours or 60 hot flushes per week.
Participants were required to have moderate to severe hot flushes during ≥ 10 days of
the 2-week, drug-free run-in period (immediately before the initiation of study therapy)
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Cohen 1999 (Continued)
, as indicated in symptoms diaries. Postmenopausal status was confirmed on the basis of
≥ 12 months’ amenorrhoea or a history of bilateral oophorectomy regardless of serum
estradiol (E2) or FSH levels. Participants with 6-11 months of amenorrhoea and those
who had been hysterectomised before cessation of menses were required to have serum
E2 values ≤ 20 pg/mL and FSH values ≥ 40 mIU/mL
A prestudy washout of 4 weeks for transdermal administration, 8 weeks for oral admin-
istration, and 6 months for injection or implants was required for participants receiving
previous HRT
Exclusion criteria: clinically significant findings involving the reproductive system (e.g.
undiagnosed vaginal bleeding, abnormal Papanicolaou smear, endometrial thickness > 5
mm, or polyps) or any malignancy, uncontrolled thyroid disease, cardiovascular or other
medical complications that might confound study assessments
Interventions 0.0375 mg/d beta-estradiol transdermal patch (11 cm2) or a matching placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events were recorded in participant diaries at each study visit
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors only reported double-blind study.
No further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15/257 (6%), balanced dropouts in all
group. ITT analysis
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published report includes
all expected outcomes, including those that
were pre-specified
Other bias Low risk The study appears to be free of other
sources of bias
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De Aloysio 2000
Methods Single centre, double-blind, randomised, placebo-controlled trial
Number of centres: 1, Bologna, Italy
Number of women randomised: 156
Number of women analysed: not stated
Statistical analysis: the comparability between groups at the end of the 2-week baseline
for the mean number of hot flushes per day was tested by ANOVA, with Tukey’s HSD
test for multiple comparisons. The statistics of the Kupperman Index were based on the
last observation carried forward (LOCF). The responder rate at the end of the treatment
was analysed by the Chi2 test on the ITT participants
The secondary end points of efficacy were also tested by ANOVA, with Tukey’s HSD test
for multiple comparisons. The Kruskal-Wallis test was used for the participant’s efficacy
judgements. All comparisons between the 3 groups were performed considering a 5 % α
significance level. The Bonferroni approach to multiple comparisons was implemented
Withdrawals and losses to follow-up: n = 20.3 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Inclusion criteria: women attending the centre because of climacteric symptoms, in
natural or surgical menopause, aged over 35 years with at least 6 months since the last
regular menstruation in case of natural menopause, or at least 4 weeks from ovariectomy,
with serum FSH ≥ 40 mIU/mL and/or E2 < 30 pg/mL, and with an average number
of at least 5 hot flushes per day
Exclusion criteria: presence or history of possibly estrogen dependent tumours, undiag-
nosed vaginal bleeding, history of endometriosis, history of thrombophlebitis, thrombo-
sis or thromboembolic disease, hepatic or renal failure, severe and uncontrolled concomi-
tant diseases, presence or history of skin diseases or allergies that could affect the local
tolerability of the patch or the absorption of estradiol and HT by injection or implants
during the previous 12 months
Interventions Transdermal beta estradiol 0.025 or 0.0375 mg/d versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• a) systemic adverse events including
◦ type, severity, onset and duration and possible causal relationship with the
medication;
◦ presence and severity of breast tenderness;
◦ possible episodes of vaginal bleeding;
• local tolerability was assessed at each clinic visit;
• possible adverse reaction of the skin at the site of patch application was graded
from 0 (absence of reaction) to 9 (severe skin lesions)
Notes 13 patients (25 %) in the placebo group did not complete the study
Data on effectiveness are skewed, reported in additional tables
Risk of bias
Bias Authors’ judgement Support for judgement
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De Aloysio 2000 (Continued)
Random sequence generation (selection
bias)
Low risk Authors reported that “...eligible women
were enrolled and blindly assigned accord-
ing to a computer generated randomiza-
tion list to the following 3 parallel treat-
ment groups...”
Allocation concealment (selection bias) Low risk Authors reported that “..eligible women
were enrolled and blindly assigned accord-
ing to a computer generated randomiza-
tion list to the following 3 parallel treat-
ment groups..”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The E2 patches were manufactured in a
similar way, were without enhancers or
other excipients, had the same composition
of adhesive and were put in identical sa-
chets to assure blindness. Placebo: trans-
dermal patch identical to the previous ones
but without E2“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses: 20/156 (13%). High rate of losses
in the placebo group (33%) compared to
the intervention group (9.6% and 4%). No
ITT analysis
Selective reporting (reporting bias) Low risk The study protocol is not available. In-
cludes all expected outcomes, including
those that were pre-specified
Other bias Low risk The study appears to be free of other
sources of bias
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De Vrijer 2000
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 16 in The Netherlands
Number of women randomised: 254
Number of women analysed: 227
Statistical analysis: the primary efficacy criterion was analysed by analysis of covariance
(ANCOVA), with baseline values as covariate, and treatment and centre as factors. Ex-
ploratory analyses of secondary efficacy criteria (daytime hot flushing and Kupperman
Index) were also assessed by ANCOVA. Night sweats were summarised descriptively. All
statistical tests were carried out at the 2-sided 5% level
Withdrawals and losses to follow-up: 6 discontinued due to poor efficacy, 18 due to
adverse experiences and 3 due to administrative problems
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Healthy postmenopausal female outpatients, with or without previous HT, requiring
treatment for climacteric symptoms.Womenwith at least 8months after last spontaneous
menstrual bleeding or 6 weeks post-oophorectomy, with a mean number of seven or
moremoderate to severe hot flushes (including night sweats) per 24 h in the 14 days prior
to randomisation. In addition, all participants had to have plasma FSH and estradiol
levels in the normal postmenopausal range (i.e. > 50 IU/L and < 20 pg/mL, respectively)
Exclusion criteria: women with contraindications for HT, with recent HRT (oral, trans-
dermal or vaginal) in previous 8 weeks, implant in preceding 12 months), or with any
previous unopposed estrogen use for more than 3 months
Interventions Transdermal beta-estradiol 0.05 or 0.1 mg/d versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Frequency and severity of any adverse event
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author reported ”...patients who met the
inclusion criteria were randomized in equal
numbers to receive either E2 Matrix 0.10
mg, E2 Matrix 0.05 mg, or placebo...“
Allocation concealment (selection bias) Unclear risk No specific discussion of allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Author reported ”As the two-dosing sys-
tems were different in size in order tomain-
tain blindness a double-dummy design was
used...“
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De Vrijer 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 27/254 (11%) women withdrew or lost to
follow-up. ITT analysis
Selective reporting (reporting bias) Low risk No protocol available but study reports all
expected outcomes
Other bias Low risk The study appears to be free of other
sources of bias
Good 1999
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 26 USA
Number of women randomised: 321
Number of women analysed: 321
Statistical analysis: all statistical tests were conducted as two-tailed with a critical prob-
ability of 0.05 for declaring significance. Pearson’s Chi-squared test or Fisher’s exact
probability test were used to examine the homogeneity of study groups with respect to
nominal variables. For continuous variables, analysis was performed with study drug as
a factor. Where analysis of variance (ANOVA) assumptions were not met, the Kruskal-
Wallis non-parametric test was used to compare study-drug groups
Withdrawals and losses to follow-up: n = 47, 16 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: reported source of funding per TheraTech Inc
Participants Healthy postmenopausal women
Inclusion criteria: age at least 21 years if surgically menopausal, 45 years if naturally
menopausal; amenorrhoeic for at least 6 months; experiencing 60 or more moderate
to severe hot flushes per week; serum estradiol concentrations ≤ 73 pmol/L and FSH
concentrations ≥ 40 mIU/mL
Exclusion criteria: previous serious dermatological disease or active skin disorder; any
psychiatric or psychological illness at time of entry; clinically significant abnormalities in
medical history, physical examination ormammography; or the use of any investigational
drug within the previous 60 days. Prospective participants were also excluded on the
basis of the following medical data obtained at the first 2 screening visits: elevated sitting
blood pressure (systolic > 165mmHg or diastolic > 95mmHg); any degree of dyskaryosis
in a cervical Pap smear; any significant abnormalities in clinical laboratory tests; or a
body weight > 130% of the participant’s ideal range according to the 1983 Metropolitan
Height and Weight Table for Women
Interventions Transdermal beta-estradiol 0.05 or 0.1 mg/d versus (CEE) Conjugated Equine estrogen
0.625mg/d or 1.25mg/d
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Good 1999 (Continued)
Outcomes • Mean weekly change in frequency and severity of moderate to severe vasomotor
symptoms from baseline
• Monitoring adverse events
Notes Period of washout: abstention from previous HT for at least 6 weeks prior to the first
screening visit (12 months in the case of estrogen implants)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Author reported double-dummy ”Admin-
istration of oral CEEwas blinded by encap-
sulation of commercially acquired tablets
(Premarin 0.625 mg) as either one or two
tablets per capsule. Each patient received
simultaneously an 1 8-cmz transdermal
system and a 36-cm2 transdermal system
twice weekly and swallowed a capsule daily.
..“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific discussion of blinding of out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses 47/321 (14.6%) No ITT analysis
Selective reporting (reporting bias) Low risk No protocol available but the study reports
all expected outcomes
Other bias Unclear risk Findings on effectiveness reported only as a
graph, so unsuitable for analysis. Reported
source of funding per TheraTech Inc
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Gordon 1995
Methods Two multicentre studies, double-blind, randomised, placebo-controlled trial
Number of centres study 1: 25 centres in USA
Number of centres study 2: 34 centres in USA
Number of women randomised study 1: 214
Number of women analysed study 1: 191
Number of women randomised study 2: 390
Number of women analysed study 2: 390
Statistical analysis: baseline weekly mean hot-flushes rates were compared between treat-
ments with an analysis of variance F test and a Wilconxon rank sum test. Analysis of
variance was performed on the change in weekly hot-flush rate and subjects and inves-
tigators’ global assessments for all participants included in the efficacy analysis. Tukey’s
multiple comparison test was used to test significant differences between treatments. A
P value of < 0.05 was considered significant
Withdrawals and losses to follow-up study 1: n = 50. 22 because of adverse events
Withdrawals and losses to follow-up study 2: n = 64. 32 because of adverse events (15
in the 0.05 mg/d, 10 in the mg/d, and 7 in the CEE groups)
Duration of trial: 11 weeks
Conflict of interest: not stated
Participants Postmenopausal women. Natural menopause participants had not menstruated for at
least 12 months and surgical menopause participants had undergone bilateral oophorec-
tomy at least 4 weeks prior to inclusion
Inclusion criteria: only women with no clinically significant medical history and no
contraindication toHTwere considered for inclusion, normal Papanicolau smear, normal
endometrial biopsy (if she had not had a hysterectomy), baseline serum estradiol level
less than 20 pg/ mL, and baseline serum FSH level greater than 50 mIU/mL. In order to
enter the 11-week treatment phase of the study, potential subjects must have experienced
aminimum of 5moderate to severe hot flushes per week, or a minimum of 15 hot flushes
of any severity per week, for 2 consecutive weeks
Exclusion criteria: women with no clinically significant medical history and contraindi-
cation for HT. Subjects qualified after having performed a examination physical, an elec-
trocardiogram and laboratory tests (complete blood count, serum electrolytes, liver and
renal function tests, total protein and albumin, cholesterol, pregnancy test if appropriate
and urinalysis)
Washout: Injectable HT had to be discontinued 12 weeks prior to entering the qual-
ification period and progesterone and other steroid compounds capable of interacting
with the study medications were prohibited during these trials
Interventions Transdermal beta-estradiol 0.05 or Transdermal beta-estradiol 0.1 versus placebo (study
1)
Transdermal beta-estradiol 0.05 versus 0.1 mg/d versus (CEE) conjugated Equine estro-
gen 0.625 mg/d (study 2)
Outcomes • Mean weekly change in frequency and severity of moderate to severe vasomotor
symptoms from baseline
• Any reactions on site of application, lessening of patch adhesion
Notes Highest withdrawal rates were in placebo (30%) and 0.05 mg beta-estradiol groups
(26%) vs 0.1 mg beta-estradiol group (13%) because of inadequate therapeutic response
(P value < 0.05) (study1)
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Gordon 1995 (Continued)
Data unsuitable for analysis reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Authors reported “At each centre , quali-
fied subjects in each study were randomly
assigned to one of three treatments groups’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported ”To preserve blinding
subjects randomized to the 0.05 mg estra-
diol group also wore 25 cm placebo patch.
..“ (study 1) . ”Blinding was preserved in a
manner similar to that employed in study
1...“ (study 2)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up: 50/191 study 1 (26%
(30% losses in the intervention group and
unbalanced with control groups.)) 64/390
study 2 (16%) No ITT analysis
Selective reporting (reporting bias) Unclear risk No protocol available, limited reporting of
adverse events
Other bias Low risk No other source of potential bias detected
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Haines 2009
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 5 centres in Asia
Number of women randomised: 165
Number of women analysed: 161
Statistical analysis: the relative change in the frequency of hot flushes from baseline
to week 12 was compared between treatment groups using a 2-sided Wilcoxon rank-
sum (Mann-Whitney) test. The null hypothesis tested was the assumption of equal
distributions of the primary target variable in both treatment groups
Withdrawals and losses to follow-up: n = 14, 4 in the E2 group and 10 in the placebo
group, because 5 never started treatment or had unknown status, 1 adverse event, 3 for
withdrawal of consent, 4 were lost to follow-up and one discontinued for ‘other’ reasons
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Women were eligible for the study if they were aged between 40 and 65 years, had
undergone natural menopause
Inclusion criteria: postmenopausal status was confirmed on the basis of 12 months’
amenorrhoea or 6 months’ amenorrhoea with serum FSH ≥ 40 m IU/mL or bilateral
oophorectomy (6 weeks postsurgery) and had at least 24 hot flushes (of any severity)
within a 7-day screening period
Exclusion criteria: recently used estrogen-containing products, an abnormal cervical
smear test, endometrial thickness of 5.0 mm, any condition that could interfere with
study medication or interpretation of results, concomitant use of inducers or inhibitors
of CYP3A4 or drugs effective in treating hot flushes, received anticoagulant treatment
for the past 6 months, or known severe dyslipoproteinaemia
Interventions Transdermal patch 0.014 mg beta-estradiol/day versus placebo
Outcomes • Mean weekly change in frequency of moderate to severe vasomotor symptoms
from baseline
• Adverse events; clinical laboratory evaluation
• Quality of life
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported ”Randomization was by a
centrally provided computer-generated list.
..“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors only reported double-blind study,
no further details
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Haines 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses: 14/165 (8%)
Selective reporting (reporting bias) Low risk No protocol available, but all expected out-
comes reported
Other bias Unclear risk Findings on effectiveness reported only as
a graph, so unsuitable for analysis
Honjo 2009
Methods Multicentre study, double-blind, randomised, placebo-controlled, three-parallel-group
trial
Number of centre: 23 centres in Japan
Number of women randomised: 211
Number of women analysed: 211
Statistical analysis: descriptive statistics were used to assess the data. Reductions in the
number of hot flushes with each treatment were compared using a 2-tailed t-test and
Holm’s step-down method; secondary endpoints were compared using the Wilcoxon
test, Fisher’s exact test and Holm’s step-down method. Significance was set at 5%. De-
mographic and baseline data were compared using the w2 test for categorical data and
one-way analysis of variance (ANOVA) for continuous data; significance was set at 15%
Withdrawals and losses to follow-up: n = 7, 4 in the placebo, 2 in the E2 0.5 mg and
one in the E2 1.0 mg group. No subjects discontinued due to adverse events
Duration of trial: 8 weeks
Conflict of interest: none reported
Participants Women with naturally occurring climacteric symptoms or ovarian deficiency symptoms
following bilateral oophorectomy
Inclusion criteria: women were eligible for the study if they were aged at least 40 but less
than 65 years, had experienced either natural menopause (defined as 1 year since last
menses or serum E2 ≤ 20 pg/mL and FSH ≥ 30 mIU/ mL) or bilateral oophorectomy
(1 month postsurgery) and had climacteric or ovarian deficiency symptoms, defined as
an average of at least 3 moderate or severe hot flushes per day in the 7 days before the
start of study drug administration
Exclusion criteria: women were excluded for gynaecologic (including cancer) or psycho-
logical disorders, hypertension, insulin-treated diabetes, migraine or epilepsy, history of
thromboembolism or cardiovascular disease, or recent treatment with sex steroid hor-
mones or autonomic nervous system regulators
Interventions Micronised beta-estradiol/day 0.5 or 1.0 mg versus placebo tablets once daily
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Honjo 2009 (Continued)
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events (including genital bleeding)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported ”.. Randomizationwas by
six subject batch in each centre, with each
batch including two subjects in each treat-
ment group; consecutive subjects were al-
located to treatment by random number
within the batch...“
Allocation concealment (selection bias) Unclear risk No specific discussion on allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors reported ”...double-blind...“ No
further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific discussion on blinding of out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses: 7/211 (3.3%)
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Low risk The study appears to be free of other
sources of bias
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Nielsen 2006
Methods Multicentre double-blind, randomised, placebo-controlled trial
Number of centres: 2 in Denmark
Number of women randomised: 335
Number of women analysed: 268
Treatment effect was studied on an ITT basis using the change in score fromW0 to the
last questionnaire available i.e. up toW26 for vasomotor symptoms and up toW104 for
all other dimensions. A global score was established from linear transformation of the
corresponding answers. Between-group differences in mean change scores were evaluated
with a non-parametric covariance analysis. Two-sided 95% CI of the differences were
calculated
Duration of trial: 2 years
Withdrawals and losses to follow-up: 67/335 (20%)
Conflict of interest: none declared
Participants Women, 40-65 years of age at baseline,who were less than 5 years past menopause
Ethnicity: white
Inclusion criteria: amenorrhoea for more than 12 months or for more than 6 months
and a concomitant serum level of estradiol below 0.16 nmol/L and FSH level above
42 IU/L. All women who had undergone hysterectomy had menopause confirmed by
determination of serum estradiol and FSH at least 2 months prior to study
Surgical menopause (bilateral ovariectomy): operation performed at least 6 weeks before
study
Women had to be osteopenic (BMD T score < −1) and not to complain of severe
climacteric symptoms
Interventions S21400 (intranasal beta-estradiol) micronised 150 µg per day, S21400 300 µg per day
+, or placebo or
S21400 (intranasal beta-estradiol) micronised 150 µg per day, S21400 300 µg per day
+, progesterone 200 mg/d, 14 days out of 28, or placebo (women with an intact uterus)
Outcomes • QoL was assessed based on the validated Women’s Health Questionnaire designed
for peri- and post-menopausal women. Change from baseline scores
• Any adverse events reported by the participant during the study
Notes Methods described in another publication (Nielsen 2004)
Data skewed, reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The treatment allocation lists were drawn
up and encoded by the Institut de
Recherches Internationales Servier
Allocation concealment (selection bias) Unclear risk The treatment allocation lists were drawn
up and encoded by the Institut de
Recherches Internationales Servier
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Nielsen 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors only reported double-blind study.
No further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind. No further details
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses: 67/335 (20%). ITT analysis
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Low risk The study appears to be free of other
sources of bias
Notelovitz 2000a
Methods Study design: parallel, double-blind, multicentre, placebo-controlled, randomised clin-
ical trial
Randomisation: block randomisation within each centre
Number of centres: 15 in the USA
Duration of trial: 3 months
Power calculations: yes (based on moderate to severe hot flush outcome)
Number of women randomised: 333 in to 1 of 5 treatment groups
Number of women analysed: 280 for moderate/severe hot flushes and 324 for hot flush
weekly weighted score
ITT analysis: no for moderate/severe hot flushes, yes for hot flush weekly weighted score
Losses to follow-up/withdrawals from treatment: 53/333 = 16% for moderate/severe hot
flushes and 4/333 = 1.2% for hot flush weekly weighted score
Compliance: not stated
Source of funding: supported by grants to participating institutions and Novo Nordisk
Pharmaceuticals Inc
Participants Menopausal status: peri- and post-menopausal
Age: mean 54.12 ± 4.14 years (mean ± SD) (range 40-60 years)
Ethnicity: race (n, %) in placebo, 0.25 mg E2, 0.5 mg E2, 1.0 mg E2, 2.0 mg E2
respectively:
White - 60 (91%), 62 (91%), 61 (95%), 57 (85%), 62 (91%)
Black - 3 (5%), 3 (4%), 2 (3%), 5 (7%), 1 (1%)
Hispanic - 1 (2%), 2 (3%), 1 (2%), 4 (6%), 3 (4%)
Asian/Pacific - 2 (3%), 0 (0%), 0 (0%), 1 (1%), 2 (3%)
Other - 0 (0%), 1 (1%), 0 (0%), 0 (0%), 0 (0%)
Source: study population was obtained from the investigators´ sites or through local
advertising (i.e. a mixture of clinical and general population)
Inclusion criteria: menopause symptoms persisting for more than 6 months, healthy
menopausal women with an intact uterus, 40-60 years old, at least 56 moderate-severe
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Notelovitz 2000a (Continued)
hot flushes/week, at least 6 months amenorrhoea, E2 levels≤ 20 pg/mL, FSH > 50 IU/
L
Exclusion criteria: history of endometrial hyperplasia, abnormal bleeding of unknown
origin, endometrial thickness at least 5 mm, history of estrogen-dependent tumours,
gallbladder, liver kidney or endocrine diseases except controlled thyroid disease, venous
thromboembolism, cerebrovascular accidents, myocardial infarction or ischaemic heart
disease, history of severe headache or migraines, high blood pressure, alcohol or drug
abuse, smoking > 15 cigarettes/day, weight increased more than 20% over ideal body
weight, use of steroid hormones/drugs known to influence estrogen metabolism & use
of HRT within 2 months prior to randomisation
Confirmation of ovarian failure: at least 6 months amenorrhoea, E2 levels≤ 20 pg/mL,
FSH ≥ 50 IU/L
Baseline equality: matched for age, time of amenorrhoea, weight, baseline hot flush
symptoms
Baseline symptoms: At least 56, with 72 ± 21 (mean ± SD) moderate-severe hot flushes/
week & mean hot flush weekly weighted score 183 ± 61 (mean ± SD)
Interventions Micronized beta-estradiol 0.25 or micronized beta-estradiol 0.5 mg/d or beta-estradiol
1.0 mg/d or micronized beta-estradiol 2.0 mg/d versus placebo. The HT and placebo
preparations were identical in appearance
Co-interventions: none reported
Outcomes • Mean weekly change in frequency and severity of moderate to severe vasomotor
symptoms from baseline
• Adverse event frequency
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported that ”The randomization
code was generated centrally using a block
size of five to ensure equal distribution of
treatment groups.“
Allocation concealment (selection bias) Unclear risk Authors reported that ”On entry, subjects
were assigned to the lowest available ran-
domization number for each site.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported that ”All study drugswere
identical in appearance and packaging, and
were manufactured and supplied by Novo
Nordisk A/S, Bagsvaerd, Denmark.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Author reported that ”...serum samples col-
lected during therapy were analyzed at the
end of the study to preserve masking of
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Notelovitz 2000a (Continued)
treatment allocation of all centres and per-
sonnel related to conduct of this study.“
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses 53/333 (16%)
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Unclear risk Findings on effectiveness reported only as a
graph, so unsuitable for analysis. Supported
by grants to participating institutions and
Novo Nordisk Pharmaceuticals Inc
Notelovitz 2000b
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 23 in USA
Number of women randomised: 145
Number of women analysed: 145
Statistical analysis: all statistical testes were two-tailed and conducted at the 5% signifi-
cance level. The percentage change in number of hot flushes from baseline to the end for
treatment (or last available measurement) was calculated for each treatment group and
was compared with the placebo group using a 2-way fixed-effect analysis of variance. This
was also used to compare the percentage change from baseline to the end of treatment
in the mean number of moderate or severe hot flushes per day. Comparisons between
active treatment groups versus placebo for subjects free of hot flushes were made using
Fisher’s exact test. For mean daily hot flushes per week analysis of covariance was used;
P values were calculated from t-tests on least square means
Withdrawals and losses to follow-up: n = 23. Withdrawals because of adverse events not
reported
Duration of trial: 12 weeks
Conflict of interest: none declared
Participants Healthy postmenopausal women who exhibited moderate to severe vasomotor symp-
toms. The following groups were included: naturally postmenopausal women aged 40-
60 years (women who had not experienced menses for at least 12 months before start of
the study), women who had undergone hysterectomy, and women aged 25-60 years who
had undergone bilateral oophorectomy with or without hysterectomy (eligible 3 weeks
after surgery)
Inclusion criteria: presence of an average of 8 or more moderate to severe hot flushes
per day during the 14 consecutive days before the start of drug administration, FSH
hormone levels were required to be ≥ 40 mIU/L and ≥ 30 mIU/L for subjects with
and without prior HT, respectively, whose menopause was natural or surgically induced,
serum estradiol levels had to be ≤ 20 pg/ml
Exclusion criteria : exposure to injectable or implantable sex steroids within 6 months
of admission and hypersensitivity to study drug ingredients
Interventions Oral beta-estradiol 0.5 or 1 mg/d versus placebo
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Notelovitz 2000b (Continued)
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events were recorded by the investigator at each visit
Notes Period washout: abstention from previous HT for at least 6 weeks before the pre-ran-
domisation visit and 8 weeks before the randomisation visit
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors reported ”randomized“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors reported ”Double-blind“. No fur-
ther details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific discussion on blinding of out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses 23/145 (16%) ITT analysis
Selective reporting (reporting bias) Low risk Includes all expected outcome
Other bias Unclear risk Authors reported ”The protocol was
amended because of unfavorable rates of
bleeding/spotting noted with combina-
tions of 2 mg E2 and NGM used in comi-
tant studies.“
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Rovati 2000
Methods Multicentre study with a prospective, randomized, double-blind, placebo-controlled,
parallel-group
Number of centres: 15 in Italy
Number of women randomised: 311
Number of women analysed: 277
Statistical analysis: Frequency of patient dropouts and/or use of rescue medication were
compared using the x2 test or Fisher’s exact test, as appropriate. Groups were compared
at the end of the 2-week baseline for the primary efficacy outcome, i.e. the mean number
of hot flushes per day, using single-factor ANOVA, with Tukey’s HSD test for multiple
comparisons
Withdrawals and losses to follow-up: n = 34, 5 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Women in natural or surgical menopause
Inclusion criteria: women with at least 6 months since the last regular menstruation in
the case of natural menopause or at least 8 weeks from ovariectomy, with serum FSH
> 50 mIU/mL and E2 < 20 pg/mL, and with an average of at least seven moderate to
severe hot flushes per day
Exclusion criteria: participants excluded were those with known or suspected breast
cancer; history of possible estrogen-dependent tumours; pathological results from the
cervical smear performed at enrolment, any mammography examination, endometrial
biopsy or vaginal ultrasound; undiagnosed genital bleeding; history of endometriosis;
active thrombophlebitis or thromboembolic disorders; hepatic or renal failure; severe and
uncontrolled concomitant diseases; presence or history of skin diseases or allergies that
could affect the local tolerability of the patch or the absorption beta-estradiol ,alcohol or
drug abuse; psychiatric disorders; or any other factor limiting the ability of participants
to understand the aim/procedures or to give their informed consent
Interventions Transdermal beta-estradiol 0.025 mg/d or 0.050 mg/d versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Systemic adverse events with their type, severity, onset and duration, and possible
causal relationship with medication
Notes Washout period: HT by injection or implant during the previous 12 months; women
with a uterus who had received unopposed estrogen treatment for more than 3 months
Data on effectiveness skewed and unsuitable for analysis. Reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported “...eligible women were
enrolled and blindly assigned according to
a computer-generated randomization list
to the following four parallel treatment
groups...”
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Rovati 2000 (Continued)
Allocation concealment (selection bias) Unclear risk No specific discussion on allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors reported “The seven-day patches
were manufactured in a similar way, are
without absorption enhancers or other ex-
cipients, have the samematrix composition
and were put in identical sachets to assure
double blindness...”
In case of poor symptom control, Derm-50
was used as open-label rescue medication“
Potential introduced by use of open-label
rescuemedication; there was between-arms
difference in the number of women who
opted for rescue
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses 34/277 (11%) 21% of the placebo
group dropped out to move to open-label
medication (for this reason) vs 8% in the 0.
025 mg/d or 3% 0.050 mg/d transdermal
beta-estradiol groups. ITT analysis
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Low risk No other source of potential bias identified
Simon 2006
Methods Multicentre, randomised, double-blind, placebo-controlled trial
Number of centres: 37 in USA
Number of women randomised: 200
Number of women analysed: 200
Statistical analysis: Between-group differences in mean reduction from baseline in fre-
quency of hot flush counts were assessed using analysis of covariance (ANCOVA). Treat-
ment efficacy was assessed on the ITT population, defined as all randomised participants
who received one or more doses of study medication. Tests comparing treatment groups
were 2 sided and performed at the 0.05 level of significance
Withdrawals and losses to follow-up: n = 17 (10 participants receiving MNPEE and 7
receiving placebo emulsion) 5 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: not declared
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Simon 2006 (Continued)
Participants Postmenopausal women with 7 or more moderate to severe hot flushes per day
Inclusion criteria: more than 12 months of amenorrhoea or more than 6 months of
amenorrhoea if accompanied by serum levels of FSH > 40 mIU/mL and serum estradiol
< 20 pg/mL. Women who had experienced 120 or more moderate to severe hot flushes
over 2 weeks of the screening period, hysterectomy, either with or without bilateral
oophorectomy, were eligible for the study if surgery was performed 1 year or more before
study entry, normal or benign pelvic examination and Papanicolaou smear, and a normal
or benign mammogram within 9 months before study entry
Exclusion criteria: participants were ineligible if they had received oral or transdermal
HT within 2 months before study entry, within 3 months for implantable HT, and
within 6 months for injectable HT. Women with a history of breast, cervical, or uterine
cancer or any other malignancy and chronic dermatologic conditions that required top-
ical maintenance therapy, a history of cerebral vascular disease, coronary artery disease,
myocardial infarction, uncontrolled hypertension, undiagnosed abnormal vaginal bleed-
ing, endocrine disease other than controlled thyroid disease on stable doses of therapy,
and allergy or hypersensitivity either to estrogens or to any constituents of this topical
medication
Interventions Micellar nanoparticle beta-estradiol emulsion (MNPEE containing 8.6mg of beta-estra-
diol) versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events were assessed throughout the study and were categorised using
standard criteria
Notes Data on effectiveness skewed. Reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors reported ”...were then randomized
to receive eitherMNPEE or placebo for 12
weeks.“
Allocation concealment (selection bias) Unclear risk No specific discussion on allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported ”Micellar nanoparticle
estradiol emulsion (containing 8.6 mg of
17B -estradiol in 3.45 g of emulsion) or
placebo was administered in identical foil-
packed pouches...“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific discussion on blinding of out-
come assessment
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Simon 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses: 17/200 (8.5%), ITT analysis
Selective reporting (reporting bias) Low risk No protocol available but reports all ex-
pected outcomes
Other bias Low risk No other source of potential bias detected
Simon 2007
Methods Multicentre, randomised, double-blind, placebo controlled, parallel-group trial
Number of centres: 28 sites in USA and 2 sites in Canada
Number of women randomised: 484
Number of women analysed: 457
Statistical analysis: for all efficacy variables an adjustment for multiple testing was per-
formed using Dunnett’s test. Comparison of the treatment groups with respect to other
quantitative variables were based on a 2-way analysis of variance model, including factors
for centre, treatment, and centre-by-treatment interaction. For either model, the interac-
tion termwas removed from the final model if not statistically significant (P > 0.10). Each
dose group was compared with placebo using Dunnett’s test, with comparisons based on
the least squares means derived from the analysis of covariance or analysis of variance.
Comparability of treatment groups with respect to categorical variables was based on the
Cochrane Mantel-Haenszel general association statistic with centre as the stratification
factor followed by the Mantel-Haenszel test if a statistically significant treatment group
difference was found
Withdrawals and losses to follow-up: n = 27. 9 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: none declared
Participants Women aged 18 years or older who had undergone natural (amenorrhoea for 12 months
or more) or surgical menopause (bilateral oophorectomy with or without hysterectomy)
6 months or more before screening
Inclusion criteria: serum estrogens less than 20 pg/mL, FSH more than 40 IU/mL, and
BMI of 18-35 kg/m2. Eligible participants recorded the number, time, and severity (0.
none; 1, mild; 2, moderate; or 3, severe) of hot flushes over the first 14 days of a 3-4-
week screening period. Participants who experienced 60 or more moderate to severe hot
flushes each week and were otherwise eligible had blood taken to measure serum E2 and
entered a 1-week single-blind placebo lead-in period, during which they applied placebo
gel once daily
Exclusion criteria: women with history of estrogen-dependent neoplasia; endometrial
hyperplasia; active hepatic, gallbladder, renal, or endocrine disease other than controlled
thyroid abnormalities; or if they were receiving concomitant medications that could
potentially interfere with hot flush frequency, severity, or their assessment
Interventions Beta-estradiol gel 0.87 g/d (= 0.52 mg/d estradiol) or beta estradiol gel 1.7 g/d (= 1.02
mg/d estradiol) or beta-estradiol gel 2.6 g/d (= 1.56 mg/d estradiol/) versus placebo
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Simon 2007 (Continued)
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• The overall incidence of treatment-emergent adverse events were reported
Notes Data on effectiveness skewed; reported in an additional table
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported that participants ”... were
randomly assigned to groups and entered
the 12-week double blind treatment pe-
riod...“ ”Initially, participant numbers were
randomly allocated in blocks of three and
in a 1:1:1 ratio to E2 gel 1.7 g/d (1.02 mg
E2), E2 gel 2.6 g/d (1.56mgE2) or placebo
gel using a computer-generated randomiza-
tion list...“
Allocation concealment (selection bias) Unclear risk Study co-ordinators assigned treatment
numbers to participants entering the 12-
week double-blind treatment period
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported that ”Participants, in-
vestigators, and outcome assessors were
blinded to treatment assignment, and no
unblinding occurred during the trial... par-
ticipants applied the study drug from two
metered-dose bottles (0.87 g gel per pump
actuation), one labelled Bottle A and the
other Bottle B, that contained placebo gel
or E2 gel as necessary to deliver the appro-
priate treatment and dose.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Authors reported that ”Participants, in-
vestigators, and outcome assessors were
blinded to treatment assignment, and no
unblinding occurred during the trial...“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses: 27/484 (5.6%) 7% discontinued in
the placebo group, 3% discontinued in the
0.87 g group, 7% discontinued in the 1.7
g group. ITT analysis
Selective reporting (reporting bias) Low risk No protocol available but reports all ex-
pected outcomes
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Simon 2007 (Continued)
Other bias Low risk No other source of potential bias detected
Speroff 1996a
Methods The trial publication reports two independent RCTs. Speroff 1996a is reported as Study
1 in the publication
Multicentre randomised, double-blind, placebo-controlled trial
Number of centres: 17 in USA
Number of women randomised: 213
Number of women analysed: 170
Statistical analysis: analysis of covariance was used to compare the frequency of hot
flushes per week between treatment groups within each study for each of the 12 weeks
of the study. Estradiol-estrone ratios of mean observed concentrations were calculated at
each sampling time
Duration of trial: 12 weeks
Withdrawals and losses to follow-up: 43/213 (20%). High rate of losses in the placebo
group (30%) compared to the intervention group (7% and 11%)
Conflict of interest: this study was supported by Warner Chilcott, a division of Galen
Holdings PLC, which has developed this product
Participants Naturally menopausal women, all with prior hysterectomy
Inclusion criteria: women with 56-140 hot flushes per week, had undergone hysterec-
tomy, were at least 50 years old and naturally menopausal or at least 35 years old and
surgically menopausal (bilateral oophorectomy at least 1month before entry), had serum
E2 concentrations of 20 pg/mL or less, and had FSH levels of 50 mlU/mL or more
Exclusion criteria: women with contraindications to beta-estradiol replacement therapy
or with a skin condition that might be exacerbated by the use of a transdermal system
or that might mask a dermatologic reaction to the system
Interventions Transdermal system delivering 0.02 mg and 0.04 mg of beta-estradiol versus placebo
transdermal system
Outcomes • Mean reduction of hot flushes per week from baseline
• Adverse events based on review of participant diary cards
Notes Data on effectiveness are skewed, reported in additional tables
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported that ”each centre was
packaged according to a computer-gener-
ated randomisation code“
Allocation concealment (selection bias) Unclear risk Not reported
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Speroff 1996a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported that: ”E2 and placebo
transdermal systems were identical in ap-
pearance, and investigators, study staff, and
subjects remained blinded to treatment un-
til the study was completed and the results
were analysed“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Authors reported that: ”E2 and placebo
transdermal systems were identical in ap-
pearance, and investigators, study staff, and
subjects remained blinded to treatment un-
til the study was completed and the results
were analysed“
Incomplete outcome data (attrition bias)
All outcomes
High risk 43/213 (20%) participants not included in
analysis
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Unclear risk Reported source of funding per Warner
Chilcott
Speroff 1996b
Methods The trial publication reports two independent RTCTs. Speroff 1996b is reported as
Study 2 in the publication
Multicentre randomised, double-blind, placebo-controlled trial
Number of centres: 17 in USA
Number of women randomised: 111
Number of women analysed: 91
Statistical analysis: analysis of covariance was used to compare the frequency of hot
flushes per week between treatment groups within each study for each of the 12 weeks
of the study Estradiol-estrone ratios of mean observed concentrations were calculated at
each sampling time
Duration of trial: 12 weeks
Withdrawals and losses to follow-up: 20/111 (18%)
Conflict of interest: this study was supported by Warner Chilcott, a division of Galen
Holdings PLC, which has developed this product
Participants Naturally menopausal women, all with prior hysterectomy
Inclusion criteria: women with 56-140 hot flushes per week, had undergone hysterec-
tomy, were at least 50 years old and naturally menopausal or at least 35 years old and
surgically menopausal (bilateral oophorectomy at least 1month before entry), had serum
E2 concentrations of 20 pg/mL or less, and had FSH levels of 50 mlU/mL or more
Exclusion criteria: women with contraindications to beta-estradiol replacement therapy
or with a skin condition that might be exacerbated by the use of a transdermal system
or that might mask a dermatologic reaction to the system
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Speroff 1996b (Continued)
Interventions Transdermal system delivering 0.02 mg and 0.04 mg of beta-estradiol versus placebo
transdermal system
Outcomes • Mean reduction of hot flushes per week from baseline
• Adverse events based on review of participant diary cards
Notes Data on effectiveness are skewed, reported in additional tables
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors reported that ”each centre was
packaged according to a computer-gener-
ated randomisation code“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Authors reported that: ”E2 and placebo
transdermal systems were identical in ap-
pearance, and investigators, study staff, and
subjects remained blinded to treatment un-
til the study was completed and the results
were analysed“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Authors reported that: ”E2 and placebo
transdermal systems were identical in ap-
pearance, and investigators, study staff, and
subjects remained blinded to treatment un-
til the study was completed and the results
were analysed“
Incomplete outcome data (attrition bias)
All outcomes
High risk 20/111 (18%) participants not included in
analysis. High rate of losses in the placebo
group (30%) compared to the intervention
group (7% and 11%)
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Unclear risk No wash out period. Reported source of
funding per Warner Chilcott
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Utian 1999
Methods Multicentre, double-blind, randomised, placebo-controlled trial, phase-III clinical trial
in 4 parallel groups
Number of centres: 26 in USA
Number of women randomised: 196
Number of women analysed: 167
Statistical analysis: Homogeneity between the 4 treatment groups at baseline was tested
statistically with χ2 tests, the Fisher exact test, Cochrane Mantel-Haenszel tests, or
nonparametric analysis of variance. Within-group comparisons were performed with
the Wilcoxon signed rank test. Between-group comparisons for vasomotor symptoms
and laboratory tests were performed with analysis of variance, followed by comparisons
against placebo for vasomotor symptoms by means of the Dunnett test. 2-sided tests
with a significance level of 5% were used. Percentages were calculated on the basis of the
number of participants on whom data were available. Mean values are given with the
SD unless otherwise stated
Withdrawals and losses to follow-up: n = 20. 7 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: not stated
Participants Women with signs of estrogen deficiency, particularly vasomotor symptoms consecutive
to natural or surgical menopause
Inclusion criteria: amenorrhoeic for at least 12months, or 6monthswith an estradiol level
< 20 pg/mL and FSH level of 50 mIU/mL, or ovariectomised (bilateral oophorectomy
for a benign reason) for at least 6 weeks. Particpants were to be highly symptomatic,
with an average of at least 56 moderate to severe vasomotor symptoms per week (hot
flushes and nocturnal sweating) during the 14-day symptom self-evaluation period that
preceded the baseline visit
Exclusion criteria: participants were not to have any marked benign mastopathy or any
malignant growth, any major abnormality in the vaginal (Papanicolaou) smear, or any
endometrial hyperplasia or carcinoma contraindicating estrogen replacement therapy.
In addition, they were not to have any severe hepatic disorder, severe hyperlipidaemia,
diabetes mellitus, or severe anaemia, as shown by the results of laboratory tests. Fur-
ther exclusion criteria were known disease or allergy contraindicating estrogen therapy,
chronic skin disease or history of cutaneous contact allergy, and cutaneous lesions on the
buttocks
Interventions Transdermal beta-estradiol patch 0.025 or 0.05 or 0.1 mg/d versus placebo
Outcomes • Mean daily change from baseline of frequency and severity of moderate to severe
hot flushes
• Adverse events (including local skin reactions and genital bleeding). At each study
visit, patch application sites were examined, information from the participant’s diary
was recorded, and participants were questioned about vasomotor symptoms, local skin
reactions, patch detachments, genital bleeding, and adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Utian 1999 (Continued)
Random sequence generation (selection
bias)
Low risk Author reported ”Study drug assignment
was carried out by means of a centralized
randomization system“
Allocation concealment (selection bias) Unclear risk No specific discussion on allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Author reported double-blind ”Three dif-
ferent sizes of the placebo patches were
used, matching each size of the active trans-
dermal systems“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific discussion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Author reported ”Efficacy was analyzed for
all treated patients evaluable for efficacy up
to week 4 and, for patients, evaluable for
efficacy up to week 12 or 13 as defined in
the protocol. Similar conclusions were ob-
tained, only the results for patients evalu-
able for efficacy up toweek 12 or 13 are pre-
sented here...“ Losses: 20/167 (12%), no
ITT analysis
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Low risk The study appears to be free of other
sources of bias
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von Holst 2000
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 34 in Germany
Number of women randomised; 186
Number of women analysed: 173
Statistical analysis: all statistical tests were performed 2-sided with a significance level
at 5%. Differences between groups were quantified by calculating 2-tailed 95% CIs.
Treatment groups were compared using theWilcoxon rank-sum test. Additionally, post-
menopausal complaints were analysed based on changes in specified symptoms after 3
treatment cycles during the double-blind, placebo-controlled phase II using the O’Brien
method (non-parametric set-up)
Withdrawals and losses to follow-up: n = not reported. 18 because of adverse events (7
placebo)
Duration of trial: 12 weeks
Conflict of interest: none declared
Participants Hysterectomised women with postmenopausal symptoms
Inclusion criteria: surgical postmenopausal status (bilateral oophorectomy) more than 3
months prior to inclusion in the study. Normal gynaecological history and examination,
serum estradiol (E2) levels less than 30 pg/ml and FSH levels greater than 30 IU/ml.
All of the women had at least 20 hot flushes per week within the last month prior to
screening and an overall Kupperman Index greater than 20
Exclusion criteria: all those who had received any of the following prior to enrolment:
sex hormones taken orally within the last 28 days; locally-applied sex hormones within
the last 21 days or injectable sex hormones within the last 6 months
Interventions Transdermal beta-estradiol 0.05 mg/d versus placebo
Outcomes • Mean weekly change in frequency and severity of moderate to severe vasomotor
symptoms from baseline
• Adverse events whether reported by the participant or observed by the investigator
were recorded
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors reported ”...multicentre, random-
ized, double blind clinical study with
an initial screening phase (phase I), a
3-month double-blind placebo-controlled
phase (phase II) and a 3-month open fol-
low-up phase (phase III)..“ No specific dis-
cussion
Allocation concealment (selection bias) Unclear risk Not reported
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von Holst 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No specific discussion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific discussion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses: 18/173 (10%). ITT analysis: yes
Selective reporting (reporting bias) Low risk No protocol available, but reports all ex-
pected outcomes
Other bias Low risk Standard deviations not reported. These
were imputed by the review authors
Wiklund 1993
Methods Multicentre, double-blind, randomised, placebo-controlled trial
Number of centres: 15 in Sweden
Number of women randomised: 242
Number of women analysed: 223
Statistical analysis: the mean individual differences in quality of life and self-rated post-
menopausal symptoms before and after therapy were tested with Wilcoxon’s test. Only
2-tailed tests were used, and the underlying distributions were all close to the Gaussian
one (without bimodal or skewed patterns). The first analysis was based on the overall or
total scores. In cases of statistically significant differences P < 0.01) a second analysis was
performed in a similar fashion with the sub scales or dimensions of the questionnaires
Withdrawals and losses to follow-up: n = not reported. 18 because of adverse events
Duration of trial: 12 weeks
Conflict of interest: none declared
Participants Postmenopausal women between 45 and 65 years old requiring HRT for climacteric
symptoms were included
Inclusion criteria: all the women had had their last menstruation at least 6 months
previously
Exclusion criteria: women with surgically induced menopause, previous or current es-
trogen-dependent tumour, other current malignant or life-threatening disease, severe
metabolic, endocrine, or gastrointestinal disease, concomitant heart disease, insulin-
treated diabetes, uncontrolled hypertension, endometriosis, undiagnosed vaginal bleed-
ing, active skin disease, and unstable medical conditions such as rheumatoid arthritis or
chronic obstructive lung disease. Women with psychiatric disorders and/or those receiv-
ing continuous tranquilliser or antidepressant therapy
Interventions Transdermal beta-estradiol 0.05 mg/d versus placebo
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Wiklund 1993 (Continued)
Outcomes Mean change from baseline for vasomotor symptoms score (Index Kupperman) and
quality-of-life measures during treatment measure used the questionnaires: Psychological
General Well-Being Index, Nottingham Health Profile and Women’s Health Question-
naire, McCoy Sex Scale. Self-rating scale of climacteric symptoms (VAS). Any events
or side effects reported by the participant during the study were graded according to
severity (mild, moderate, severe) and related to the trial treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors reported ”The women were
blindly and randomly allocated to either
transdermal beta-estradiol therapy, 50 J.Lg/
24 hours, or placebo given as patches twice
a week...“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, matching placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described in detail
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses: 19/223 (8%)
Selective reporting (reporting bias) Low risk The study protocol is not available but it is
clear that the published reports include all
expected outcomes
Other bias Low risk The study appears to be free of other
sources of bias
BMI: body mass index
FSH: follicle stimulating hormone
HT: hormone therapy
HRT: hormone replacement therapy
ITT: intention-to-treat
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akhila 2006 Comparison is oral conjugated equine estrogen 0.625 mg versus gel beta-estradiol 0.75 mg versus patch
beta-estradiol 1.8mgplusmedroxyprogesterone acetate 2,5mg, which does notmeet the selection criteria
Bachmann 2003 This study is not a RCT
Bachmann 2007 Comparison is beta-estradiol gel + levonorgestrel vs placebo, which does not meet the selection criteria
for this review
Bachmann 2008 Comparison is beta-estradiol gel + levonorgestrel vs placebo, which does not meet the selection criteria
of this review
Ben-Chetrit 2005 Comparison is ring beta-estradiol 0.36 g + progesterone 3.6 g versus ring beta-estradiol 0.36 g + proges-
terone 1.8 g , which does not meet the selection criteria of this review
Carranza-Lira 2006 Comparison is esterified conjugated estrogens (ECE) 0.156 mg/d (ultra low-dose) versus ECE 0.312
mg/d (low-dose), which does not meet the selection criteria of this review
Castelo-Branco 2010 This study is not a RCT
Chung 1996 Included participants without hot flushes
Conaway 2011 This study is not a RCT
Cortes-Bonilla 2015 Comparison is parenteral 0.5mg beta-estradiol+15mg progesterone versus 1mg parenteral beta-estradiol
+20mg progesterone versus parenteral 1mg beta-estradiol +30mg progesterone,which does not meet the
selection criteria of this review
Darj 1991 Compares treatment with different doses of micronised progesterone, all in combination with 0.2mg
beta-estradiol plus. No group had placebo or non-bioidentical hormones
Diem 2006 Does not meet the selection criteria for this review as to the type of participants
Ettinger 2007 This study is not a RCT
Files 2011 This study is not a RCT
Formby 2011 This study is not a RCT
Ganz 2002 This study is not a RCT
Gass 2004 Comparison is beta-estradiol buccal tablets + medroxyprogesterone acetate vs placebo, which does not
meet the selection criteria for this review
Hedrick 2009 Comparison 0.25, 0.5, or 1.0 g beta-estradiol 0.1% gel plus10 mg/d oral medroxyprogesterone for 14
days versus placebo,which does not meet the selection criteria for this review
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(Continued)
Iftikhar 2011 This study is not a RCT
Jensen 1987 Participant group do not meet review inclusion criteria. Participants were part of a study of post-
menopausal osteoporosis and did not all have vasomotor symptoms (incidence of hot flushes was 80%
in one group and 93% in the other group at study commencement)
Lacut 2004 Participant group do not meet review inclusion criteria. Purpose of study was to investigate role of
transdermal estrogen for preventing heart disease, and vasomotor symptoms were not an inclusion
criterion; not stated whether women were symptomatic
Lindh 2004 Comparison is beta-estradiol + exercise vs sedentary women, which does not meet the selection criteria
for this review
Lopes 2000 Comparison intranasal beta-estradiol 300 mg/day or patch 50 mg/day plus dydrogesterone 10 or 20 mg/
d for 14 days per 28-day cycle, which does not meet the selection criteria for this review
Lubbert 1997 Comparison is beta-estradiol matrix patch (50 mg 17 /beta-estradiol/day) twice weekly, either continu-
ously (8 patches/cycle) vs cyclically (6 patches/cycle, i.e. 3 weeks on, 1 week off ) with or without an oral
progestogen, which does not meet the inclusion criteria for this review
MacLennan 2009 This study is not a RCT
Marslew 1991 Comparison is 2mg oestradiol valerate combined with cyproterone acetate, medroxyprogesterone acetate
or levonorgestrel vs I.5 mg beta-oestradiol combined with desogestrel vs placebo, which does not meet
the selection criteria for this review
Marslew 1994 Comparison is beta-oestradiol + cyproterone acetate vs beta-oestradiol + desogestrel which does not meet
the selection criteria for this review
Mather 2000 Comparison is beta-estradiol vs beta-estradiol + progesterone vs progesterone which does not meet the
selection criteria for this review. Outcomes do not include hot flushes
Mirkin 2015 This study is not an RCT. This report summarizes the methodology of the REPLENISH trial
Mizumuna 2011 Comparison is transdermal beta-estradiol 1.08 mg/d + medroxyprogesterone acetate or 0.9g /day trans-
dermal beta-estradiol+ medroxyprogesterone acetate 5 mg vs placebo which does not meet the selection
criteria for this review
Odabasi 2007 Comparison is intranasal beta-estradiol + progesterone gel vs beta-estradiol + progesterone gel, which
does not meet the selection criteria for this review
Panay 2007 Comparison is beta-estradiol + norethisterone vs placebo which does not meet the selection criteria for
this review
Pélissier 2001 Comparison is beta-estradiol patch + oral chlormadinone acetate versus beta- estradiol patch+ oral
micronized progesterone so bioidentical versus bioidentical , which does not meet the selection criteria
for this review
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(Continued)
Rosano 2000 Comparison is beta-estradiol + progesterone gel vs medroxyprogesterone which does not meet the selec-
tion criteria for this review
Ryan 2001 Comparison is conjugated equine estrogens + medroxyprogesterone acetate vs conjugated equine +
progesterone which does not meet the selection criteria for this review
Serfaty 2003 This study is not a RCT
Sitruk 2007 This study is not a RCT
Siyam 2013 This study is not a RCT
Skarsgard 2000 This study is not a RCT
Somunkiran 2007 Comparison is oral beta-estradiol vs tibolone which does not meet the selection criteria for this review
Sood 2011 This study is not a RCT
Sood 2013 Outcomes do not include hot flushes
Studd 1999 Comparison is intranasal beta-estradiol + medroxyprogesterone acetate 5 mg vs estradiol valerate 1 mg
or 2 mg + medroxyprogesterone acetate 5 mg vs placebo which does not meet the selection criteria for s
this review
Suvanto-luukkonen 1997 This study is not a RCT
Vartiainen 1993 This study is not a RCT
Veerus 2013 Comparison is 0.625 conjugated beta-estradiol + medroxyprogesterone acetate 2.5 mg or 0.625 conju-
gated beta-estradiol + medroxyprogesterone acetate 5 mg vs placebo which does not meet the selection
criteria for s this review
Whelan 2013 Comparison is progesterone cream vs placebo which does meet the selection criteria for this review
Wihlbacka 2005 Comparison is beta-estradiol vs beta-estradiol + progesterone which does not meet the selection criteria
for this review
Wolfe 1994 Comparison is Norgestrel dl or beta-estradiol or Norgestrel dl + beta-estradiol vs placebo which does not
meet the selection criteria for this review
Yesildaglar 2004 Does not meet the selection criteria for this review as to the type of participants
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D A T A A N D A N A L Y S E S
Comparison 1. Transdermal beta estradiol patch vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of hot flushes 4 793 Std. Mean Difference (IV, Fixed, 95% CI) -0.68 [-0.83, -0.53]
2 Intensity of hot flushes 2 393 Mean Difference (IV, Fixed, 95% CI) -19.94 [-24.86, -15.
02]
2.1 Beta-estradiol patch 0.025
mg/d
2 198 Mean Difference (IV, Fixed, 95% CI) -17.49 [-24.61, -10.
36]
2.2 Beta-estradiol patch 0.
0375 mg/d
1 78 Mean Difference (IV, Fixed, 95% CI) -11.0 [-22.59, 0.59]
2.3 Beta-estradiol patch 0.05
mg/d
1 117 Mean Difference (IV, Fixed, 95% CI) -28.0 [-36.38, -19.
62]
3 Adverse effects 9 1822 Odds Ratio (M-H, Random, 95% CI) 2.14 [1.29, 3.54]
3.1 Beta-estradiol patch 0.014
mg/d
1 160 Odds Ratio (M-H, Random, 95% CI) 1.85 [0.95, 3.59]
3.2 Beta-estradiol patch 0.025
mg/d
3 256 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.33, 3.86]
3.3 Beta-estradiol patch 0.
0375 mg/d
2 335 Odds Ratio (M-H, Random, 95% CI) 1.40 [0.88, 2.21]
3.4 Beta-estradiol patch 0.05
mg/d
6 845 Odds Ratio (M-H, Random, 95% CI) 1.94 [0.97, 3.87]
3.5 Beta-estradiol 0.10 mg/d 2 226 Odds Ratio (M-H, Random, 95% CI) 10.95 [5.62, 21.31]
4 Quality of life - beta-estradiol 0.
014 mg/d
1 165 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.35, 0.35]
5 Quality of life - beta-estradiol 0.
05 mg/d
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Nottingham Health
Profile
1 223 Mean Difference (IV, Fixed, 95% CI) -40.90 [-61.82, -19.
98]
5.2 Psychological general well-
being
1 223 Mean Difference (IV, Fixed, 95% CI) -7.0 [-11.90, -2.10]
5.3 Women’s Health
Questionnaire
1 223 Mean Difference (IV, Fixed, 95% CI) -11.4 [-14.41, -8.39]
5.4 McCoy Sex Scale 1 223 Mean Difference (IV, Fixed, 95% CI) -3.80 [-5.54, -2.06]
5.5 Self-rated symptoms 1 223 Mean Difference (IV, Fixed, 95% CI) -157.9 [-200.37, -
115.43]
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Comparison 2. Transdermal beta-estradiol gel vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse effects 3 1086 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [1.09, 1.83]
1.1 Beta-estradiol gel 0.27
mg/d
1 190 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.86, 2.80]
1.2 Beta-estradiol gel 0.37
mg/d
1 191 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.67, 2.19]
1.3 Beta-estradiol gel 0.5 mg/
d
1 182 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.56, 2.16]
1.4 Beta-estradiol gel 0.75
mg/d
1 111 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.41, 2.15]
1.5 Beta-estradiol gel 1.0 mg/
d
1 188 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.72, 2.79]
1.6 Beta-estradiol gel 1.5 mg/
d
2 224 Odds Ratio (M-H, Fixed, 95% CI) 2.11 [1.20, 3.69]
Comparison 3. Oral beta-estradiol vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of hot flushes 2 356 Std. Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.03, -0.57]
1.1 Beta-estradiol oral 0.5 mg/
d
2 178 Std. Mean Difference (IV, Fixed, 95% CI) -0.62 [-0.94, -0.30]
1.2 Beta-estradiol oral 1.0 mg/
d
2 178 Std. Mean Difference (IV, Fixed, 95% CI) -0.98 [-1.31, -0.65]
2 Adverse effects 3 433 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.84, 1.96]
2.1 Beta-estradiol oral 0.5 mg/
d
2 178 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.52, 1.93]
2.2 Beta-estradiol oral 1.0 mg/
d
3 217 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.81, 2.73]
2.3 Beta-estradiol oral 2.0 mg/
d
1 38 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [0.41, 8.63]
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Comparison 4. Topical beta-estradiol emulsion vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse effects 1 200 Odds Ratio (M-H, Fixed, 95% CI) 1.46 [0.80, 2.66]
1.1 Micellar nanoparticle
beta-estradiol 8.6 mg/day
1 200 Odds Ratio (M-H, Fixed, 95% CI) 1.46 [0.80, 2.66]
Comparison 5. Intranasal beta-estradiol vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Frequency of hot flushes 1 458 Mean Difference (IV, Fixed, 95% CI) -3.04 [-4.05, -2.03]
1.1 Beta-estradiol 0.021mg/d 1 154 Mean Difference (IV, Fixed, 95% CI) -3.34 [-4.92, -1.76]
1.2 Beta-estradiol 0.029 mg/d 1 152 Mean Difference (IV, Fixed, 95% CI) -2.47 [-4.45, -0.49]
1.3 Beta-estradiol 0.04 mg/d 1 152 Mean Difference (IV, Fixed, 95% CI) -3.12 [-4.86, -1.38]
2 Adverse effects 1 458 Odds Ratio (M-H, Fixed, 95% CI) 1.96 [1.26, 3.03]
2.1 Beta estradiol 0.021mg/d 1 154 Odds Ratio (M-H, Fixed, 95% CI) 2.03 [0.92, 4.49]
2.2 Beta estradiol 0.029 mg/d 1 152 Odds Ratio (M-H, Fixed, 95% CI) 1.99 [0.98, 4.01]
2.3 Beta estradiol 0.04 mg/d 1 152 Odds Ratio (M-H, Fixed, 95% CI) 1.85 [0.85, 4.04]
Comparison 6. Oral beta-estradiol vs CEE 0.625
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse effects 1 103 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.50, 2.87]
1.1 Beta estradiol oral 1.0 mg/
d
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.25, 3.29]
1.2 Beta estradiol oral 2.0 mg/
d
1 51 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.46, 5.02]
A D D I T I O N A L T A B L E S
Table 1. Transdermal beta-estradiol patch versus placebo: frequency of hot flushes
Comparison Measure Transdermal beta-estra-
diol
Placebo P value for difference be-
tween groups*
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Table 1. Transdermal beta-estradiol patch versus placebo: frequency of hot flushes (Continued)
0.025 mg/d beta-estra-
diol transdermal patch
vs placebo (De Aloysio
2000)
Mean reduction from
baseline in number of
hot flushes per day
83% (n = 47) 58% (n = 39) P value < 0.05
0.0375 mg/d beta-estra-
diol transdermal patch
vs placebo (De Aloysio
2000)
77% (n = 50) 58% (n = 39) P value < 0.05
0.025 mg/d beta-estra-
diol transdermal patch vs
placebo (Rovati 2000)
78% (n = 80) 50% (n = 80) P value < 0.05.
0.05 mg/d beta-estra-
diol transdermal patch vs
placebo (Rovati 2000)
93% (n = 77) 50% (n = 80) P value < 0.05.
0.025 mg/d beta-estra-
diol transdermal patch vs
placebo (Utian 1999)
86% (n = 42) 55% (n = 48) P value < 0.05
0.05 mg/d beta-estra-
diol transdermal patch vs
placebo (Utian 1999)
97% (n = 39) 55% (n = 48) P value < 0.05
0.1 mg/d beta-estra-
diol transdermal patch vs
placebo (Utian 1999)
97% (n = 39) 55% (n = 48) P value < 0.05
0.02 mg/d beta-estra-
diol transdermal patch vs
placebo (Speroff 1996a)
Mean number of hot
flushes per week at end
of study
13.4, SD 36.8 (n = 44) 21.5, SD 36.8 (n = 34) P value = 0.088
0.04 mg/d beta-estra-
diol transdermal patch vs
placebo (Speroff 1996a)
9.4, SD 35.1 (n = 39) 35.9, SD 35.1 (n = 33) P value < 0.001
0.02 mg/d beta-estra-
diol transdermal patch vs
placebo (Speroff 1996b)
13.4, SD 19.3 (n = 26) 29.8, SD 19.3-21.0 (n =
23)
P value = 0.004
0.04 mg/d beta estra-
diol transdermal patch vs
placebo (Speroff 1996b)
12.4, SD 21.0 (n = 23) 29.8, SD 19.3-21.0 (n =
23)
P value = 0.006
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Table 1. Transdermal beta-estradiol patch versus placebo: frequency of hot flushes (Continued)
0.014 mg/d beta-estra-
diol transdermal patch vs
placebo (Haines 2009)
Mean reduction from
baseline in number of
hot flushes per month
55% (n = 80) 40% (n = 80) P value < 0.01
0.05 mg/d beta estra-
diol transdermal patch vs
placebo (Gordon 1995)
Reduction from baseline
in number of hot flushes
n = 191 women included in analysis P value < 0.05
0.10 mg/d beta-estra-
diol transdermal patch vs
placebo (Gordon 1995)
P value < 0.05
*P value reported by authors
mg/d = milligrams per day
Table 2. Transdermal beta-estradiol patch versus placebo: hot flush intensity
Comparison Transdermal estradiol Placebo P for difference between groups*
0.014 mg/d transdermal estra-
diol patch vs placebo (Haines
2009)
-5.8 (n = 80) -8.4 (n = 80) P value = 0.05
*P value reported by study authors
mg/d = milligrams per day
Table 3. Transdermal beta-estradiol gel versus placebo: frequency of hot flushes
Comparison Measure Transdermal estradiol Placebo P for difference between groups*
0.27 mg/d beta-estra-
diol transdermal gel vs
placebo (Archer 2012)
Mean reduction from
baseline in number of
hot flushes per day
-5.86 -4.41 P value < 0.001
0.37 mg/d beta-estra-
diol transdermal gel vs
placebo (Archer 2012)
-8.23 -4.41 P value < 0.001
0.75 mg/d beta-estra-
diol transdermal gel vs
placebo (Archer 2003)
-7.8 (SD 4.17) -5.7 (SD 4.19) P value < 0.05
1.5 mg/d beta-
estradiol transdermal gel
vs placebo (Archer 2003)
-8.5 (SD 4.31) -5.7 (SD 4.19) P value < 0.05
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Table 3. Transdermal beta-estradiol gel versus placebo: frequency of hot flushes (Continued)
0.52 mg/d beta-estra-
diol transdermal gel vs
placebo (Simon 2007)
Proportion of women
with relief of hot flushes
at 12 weeks
61% (n = 132) 27% (n = 128) P value < 0.001
0.52 mg/d beta-estra-
diol transdermal gel vs
placebo (Simon 2007)
76% (n = 133) 27% (n = 128) P value < 0.001
0.52 mg/d beta-estra-
diol transdermal gel vs
placebo (Simon 2007)
77% (n = 64) 27% (n = 128) P value < 0.001
*P value reported by authors
mg/d = milligrams per day
Table 4. Oral beta-estradiol versus placebo: frequency of hot flushes
Comparison (n) Measure Findings
1.0 mg/d oral beta-estradiol vs placebo (n
= 27 vs 25) (Archer 1992)
Hot flush frequency at 12 weeks 91% reduction in intervention group vs
66% reduction in placebo group (P value
< 0.01)
2.0 mg/d oral beta-estradiol vs placebo (n
= 25 vs 25) (Archer 1992)
92% reduction in intervention group vs
66% reduction in placebo group (P value
< 0.01)
0.25 mg/d oral 17 beta-estradiol vs placebo
(n = 68 vs 66) (Notelovitz 2000a)
Hot flushes per week at week 12, reported
in graphical form
All doses except 0.25 mg/d were signifi-
cantly better thanplacebo at reducingmod-
erate to severe hot flushes (P value <0.001*)
, with a linear correlation for more benefit
with higher dose
0.05 mg/d oral 17 beta-estradiol vs placebo
(n = 64 vs 66) (Notelovitz 2000a)
1.0 mg/d oral 17 beta-estradiol vs placebo
(n = 67 vs 66) (Notelovitz 2000a)
2.0 mg/d oral 17 beta-estradiol vs placebo
(n = 68 vs 66) (Notelovitz 2000a)
*P value reported by study authors
mg/d = milligrams per day
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Table 5. Topical beta-estradiol emulsion versus placebo: frequency of hot flushes
Comparison Measure Topical estradiol emul-
sion
Placebo P for difference between groups*
8.6mg/d topicalmicellar
nanoparticle beta-estra-
diol emulsion vs placebo
(Simon 2006)
Hot flushes per day at 12
weeks
-11.1 (SD 6.8) -7.2 (SD 4) P value < 0.001
*P value reported by study authors
mg/d = milligrams per day
Table 6. Intranasal beta-estradiol versus placebo: quality-of-life score (Women’s Health Questionnaire) change from baseline
Dimension 150 µg/d (n = 114)
mean (SD) P value*
300 µg/d (n = 103)
mean (SD) P value*
Placebo (n = 118)
mean (SD)
Anxiety/depressed mood -0.5 (12.6)
ns
1.9 (11.8)
ns
-1.6 (10.8)
Well-being -1.0 (14.3)
ns
3.4 (16.1)
ns
-0.1 (14.8)
Somatic symptoms 0.8 (14.3)
ns
2.0 (12.1)
0.012
-1.9 (14.8)
Memory/concentration 1.8 (16.2)
0.006
4.6 (17.4)
< 0.001
-3.1 (16.9)
Vasomotor symptoms 25.1 (19.7)
< 0.001
30.5 (29.6)
< 0.001
2.3 (21.6)
Sleep problems 8.1 (21.2)
< 0.001
8.2 (17.7)
< 0.001
-1.9 (18.9)
Sexual behaviour 1.9 (21.0)
0.013
7.8 (20.3)
< 0.001
-3.5 (17.0)
Menstrual symptoms -2.3 (15.3)
0.003
-1.9 (16.1)
0.005
1.1 (0.0)
Data from Nielsen 2006
*P value compared with placebo, reported by study authors
ns = not statistically significant
mg/d = milligrams per day
84Bioidentical hormones for women with vasomotor symptoms (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Transdermal beta -stradiol patch versus conjugated equine estrogens (CEE): frequency of hot flushes
Comparison Measure Beta-estradiol (n) CEE (n) P value for difference between groups*
0.05 mg/d transdermal
beta-estradiol patch vs 0.
0625 mg/d CEE (Good
1999)
Mean change from base-
line in number of hot
flushes per week, at 12
weeks
Percentages in this ta-
ble are estimated, as data
presented in graphical
form
87% 91% P value > 0.05
0.10 mg/d transdermal
beta-estradiol patch vs 0.
0625 mg/d CEE (Good
1999)
90% 91% P value > 0.05
0.05 mg/d transdermal
beta-estradiol patch vs 1.
25 mg/d CEE (Good
1999)
87% 93% P value > 0.05
0.10 mg/d transdermal
beta-estradiol patch vs 1.
25 mg/d CEE (Good
1999)
90% 93% P value > 0.05
0.05 mg/d transdermal
beta-estradiol patch vs
0.0625 mg/d CEE (
Gordon 1995)
Mean change from base-
line in number of hot
flushes per week, at 11
weeks
62.8% (n = 130) 67.3% (n = 136) P value > 0.05
0.05 mg/d transdermal
beta-estradiol patch vs
0.0625 mg/d CEE (
Gordon 1995)
78.1% (n = 124) 67.3% (n = 136) P value > 0.05
P value compared with placebo, reported by study authors
mg/d = milligrams per day
Table 8. Oral beta-estradiol versus conjugated equine estrogens (CEE): frequency of hot flushes
Comparison Measure Beta-estradiol (n) CEE (n) P value for difference be-
tween groups*
1.0 mg/d oral beta-estra-
diol vs 0.0625 mg/d
CEE (Archer 1992)
Mean change from base-
line in frequency of vaso-
motor symptoms, at 12
weeks
91% decrease from base-
line (n = 27)
80% decrease from base-
line (n = 25)
P value > 0.05
2.0 mg/d oral beta-estra-
diol vs 0.0625 mg/d
92% decrease from base-
line (n = 25)
80% decrease from base-
line (n = 25)
P value > 0.05
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Table 8. Oral beta-estradiol versus conjugated equine estrogens (CEE): frequency of hot flushes (Continued)
CEE (Archer 1992)
1.0 mg/d oral beta-estra-
diol vs 1.25 mg/d CEE
(Archer 1992)
91% decrease from base-
line (n = 27)
95% decrease from base-
line (n = 26)
P value > 0.05
2.0 mg/d oral beta-estra-
diol vs 1.25 mg/d CEE
(Archer 1992)
92% decrease from base-
line (n = 25)
95% decrease from base-
line (n = 26)
P value > 0.05
P value compared with placebo, reported by study authors
mg/d = milligrams per day
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S O U R C E S O F S U P P O R T
Internal sources
• Brazilian Cochrane Centre, Brazil.
Brazilian Cochrane Centre to conduct the searches in LILACS
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• The analyses were stratified by dose of BHT.
• We added a new sensitivity analysis.
• We decided not to do a sensitivity analysis by outlier status, as data-driven decisions are associated with high risk of bias.
• We noted explicitly in the Methods section that we conducted separate comparisons according to the route of administration of
the intervention.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Estradiol [adverse effects; ∗therapeutic use]; Estrogens [adverse effects; ∗therapeutic use]; Estrogens, Conjugated (USP) [adverse effects;
∗therapeutic use]; Hot Flashes [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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